Depalmitoylase inhibitors and methods of use for the treatment of axonal degeneration

Inhibiting protein depalmitoylation and SARM1 activity using modulators of APTs and SARM1 enzymes addresses axon degeneration, offering therapeutic protection in neuropathological conditions.

WO2026236631A1PCT designated stage Publication Date: 2026-11-12TEMPLE UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027306
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

There is a need for compositions to treat, ameliorate, and/or prevent axon degeneration, which is a hallmark of diverse neuropathological conditions such as diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy, as existing understanding of axo-degenerative mechanisms is limited.

Method used

Administering modulators of acyl-protein thioesterases (APT)-1, APT2, ABHD family enzymes (ABHD16A, ABHD17A, ABHD17B, and ABHD17C) and SARM1 inhibitors to inhibit protein depalmitoylation and SARM1 activity, respectively, to prevent axon degeneration.

Benefits of technology

The inhibition of protein depalmitoylation and SARM1 activity effectively protects axons from degeneration, providing therapeutic benefits in conditions like diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027306_12112026_PF_FP_ABST
    Figure US2026027306_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Described herein is a method for treating, ameliorating, and / or preventing axon degeneration or associated diseases or conditions in a subject in need thereof. The method comprises administering to the subject an effective amount of a compound that downregulates acyl-protein thioesterase (APT)-1, APT2, α / β hydrolase domain-containing (ABHD) enzyme 16A, ABHD17A, ABHD17B, and / or ABHD17C.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Atorney Docket No. 394948-0104W01(00013)

[0002] DEPALMITOYLASE INHIBITORS AND METHODS OF USE FOR THE TREATMENT OF AXONAL DEGENERATION

[0003] CROSS-REFERENCE TO RELATED APPLICATIONS The present application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 63 / 803,030, filed May 09, 2025, which is incorporated herein by reference in its entirety.

[0004] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

[0005] This invention was made with government support under R01 NS094402 and F31 NS135943 awarded by the National Institutes of Health. The government has certain rights in the invention.

[0006] BACKGROUND

[0007] Axon degeneration is a hallmark of diverse neuropathological conditions. After acute injury, axons degenerate via an active process known as Wallerian degeneration (WD). Mechanistically similar “Wallerian-like'’ degeneration is seen in chronic neuropathies, including Diabetic Peripheral Neuropathy (DPN, the most common chronic complication of diabetes and chemotherapy -induced peripheral neuropathy (CIPN, a frequent side-effect of chemotherapy). A better understanding of axo-degenerative mechanisms should reveal new therapeutic strategies to preserve axon integrity and thereby ameliorate a range of neuropathologies.

[0008] Thus, there remains a need for compositions to treat, ameliorate, and / or prevent neuropathologies. The present invention satisfies this need.

[0009] SUMMARY

[0010] In some aspects, the present invention provides a method of treating, ameliorating, and / or preventing axon degeneration or an associated disease or condition in a subject in need thereof. In some embodiments, the method comprises administering to the subject a modulator of one or more selected from the group consisting of acyl-protein thioesterase (APT)-l, APT2, a / p hydrolase domain-containing (ABHD) enzyme 16A, ABHD17A, ABHD17B, and ABHD17C.

[0011] 1

[0012] 578220772Atorney Docket No. 394948-0104W01(00013)

[0013] BRIEF DESCRIPTION OF THE DRAWINGS

[0014] The following detailed description of exemplary' embodiments will be better understood when read in conjunction with the appended drawings. For the purpose of illustrating, non-limiting embodiments are shown in the drawings. It should be understood, however, that the present specification is not limited to the precise arrangements and instrumentalities of the embodiments shown in the drawings.

[0015] Fig. 1 provides anon-limiting view' of key events in Wallerian Degeneration (WD) post-injury, in accordance with some embodiments. Injury triggers a rapid intracellular calcium rise, thought to be dispensable for WD. In the next latent phase, axons remain intact but axon survival factors (most importantly NMNAT2) are degraded. NMNAT2 loss activates SARM1, which depletes NAD+, and triggers ATP loss. Mitochondria then depolarize (an event important for axonal health but dissociable from frank degeneration). A late influx of extracellular calcium is necessary for, and predictive of, axon fragmentation. Events in red are focused. Despite SARMl’s undoubted importance, this model does not preclude the existence of other axo-degenerative pathways. in WD, and some forms of axon degeneration are SARM1 -independent.

[0016] Fig. 2 illustrate certain aspects of the reversible protein palmitoylation, in accordance with some embodiments. Palmitate (gold zigzag) is added to target proteins by protein acyltransferases (PATs) and removed by ABHD family depalmitoylases.

[0017] Figs. 3A-3E demonstrate that Palmostatin B (PalmB) prevents injury- and vincristine-induced axon degeneration, in accordance with some embodiments. Fig. 3 A: Schematic of spot cultures used in Figs. 3B-3E and later Figures. Fig. 3B: Phase contrast images of DRG axons from the indicated conditions. Fig. 3C: Data from Fig. 3B; Axon degeneration at the indicated times, quantified as fragmented / total axon area. PalmB, added immediately postinjury, protects axons from degeneration. ***: p<0.001; **: p<0.01; *: p<0.05 vs injured / vehicle, ANOVA. Fig. 3D: Images of DRG axons treated with or without 40nM vincristine. Fig. 3E: Data from Fig. 3D. ****p<0.0001, ANOVA.

[0018] Figs. 4A-4C illustrate certain aspects of the quantitative comparison of ABHD family depalmitoylase protein levels in DRG axons, and show evidence that specific axonal depalmitoylases control WD, in accordance with some embodiments. Fig. 4A: Phylogenetic tree of mammalian ABHD family enzymes. ABHD enzymes with reported protein depalmitoylase activity' are in bold type, with specific inhibitors indicated. Circles indicate ABHD enzy mes identified proteomically in DRG axons. Each circle’s area is proportional to

[0019] 2

[0020] 578220772Atorney Docket No. 394948-0104W01(00013)

[0021] the integrated intensity-based absolute quantification (iBAQ) signal, a measure of relative protein abundance, from n=4 biological replicates. All known protein depalmitoylases are present in DRG axons. Fig. 4B: DRG axons, imaged after injury and treatment with the indicated compounds (4i: combination of 4 depalmitoylase inhibitors from Fig. 4A). Fig. 4C: Quantified data from Fig. 4B confirm that 4i treatment protects axons almost as effectively as PalmB. *:p<0.05; **:p<0.01; ***:p<0.001; ****:p<0.0001 compared to injured / DMSO condition at each time point, ANOVA.

[0022] Figs. 5A-5E demonstrate that axonal depalmitoylases drive WD via a SARM1-independent pathway, in accordance with some embodiments. Fig. 5A: Upper: Western blots of axonal samples, treated as indicated at the time of injury. Lower: Quantified data (n=3-4) confirm that PalmB minimally affects NMNAT2 degradation. *:p<0.05; ns: not significant vs DMSO / inj condition, ttest. Fig. 5B: Fluorescent images of SARM1 activity probe AD-la and CellMask DeepRed membrane dye (to quantify axonal area) from DRG neurons treated as indicated. Fig. 5C: Quantified data from B confirm injury -induced SARM1 activation.

[0023] SARM1 activity is blunted by PalmB but not 4i. SARM1 inhibitor DSRM-3716 (‘SARMli’) reduces ADla signal to background levels. **:p<0.01; ****:p<0.0001 vs uninjured / DMSO condition, ANOVA. Fig. 5D: Images of DRG axons 24h after treatment as indicated at the time of injury'. Fig. 5E: Quantified data from D (3 biological replicates per time point) confirm that both PalmB and 4i greatly extend axon protection afforded by SARMli, suggesting that axonal depalmitoylases drive a SARM1 -independent WD pathway.

[0024] Figs. 6A-6D demonstrate that depalmitoylase inhibitor PalmB prevents injury-induced A'Pm loss and cytosolic calcium elevation, in accordance with some embodiments. Fig. 6A: Images of TMRM signal, which reports mitochondrial membrane potential, from axons treated as indicated. Fig. 6B: Quantified data from A confirm that PalmB and SARM1 inhibitor (SARMli) both similarly protect against injury-induced A m loss. *:p<0.05, ns: not significant, ANOVA. Fig. 6C: Images of GCaMP6m fluorescence from axons treated as indicated. Fig. 6D: Quantified data from C confirm that PalmB prevents injury-induced calcium elevation. *:p<0.05, ANOVA.

[0025] Fig. 7 illustrate certain aspects of the axonal palmitoyl-proteomics study, which identified potential mediators of depalmitoylation-dependent WD, in accordance with some embodiments. Volcano plot of palmitoyl-proteins (ABE fractions) from injured DRG axons that had been treated with PalmB or vehicle. Right-shifted distribution reflects more proteins with increased palmitoylation in the injured / PalmB condition, consistent with PalmB ’s mechanism of action. Blue: proteins whose palmitoylation is increased by PalmB and which 3

[0026] 578220772Atorney Docket No. 394948-0104W01(00013)

[0027] also undergo injury-dependent depalmitoylation ("Group I’ proteins). Magenta: abundant proteins whose palmitoylation is increased by PalmB but which undergo minimal injurydependent depalmitoylation (‘Group II’ proteins).

[0028] Fig. 8 demonstrates that depalmitoylase inhibitors and SARMli additively protect axons in a CIPN model, in accordance with some embodiments. Images and quantified data for DRG spot culture axons 48h after the indicated treatments. Data are averaged from 3-6 fields per condition from a single culture, thus no statistics are shown.

[0029] Figs. 9A-9C list some non-limiting examples of isothiazole inhibitors of the S ARM1 NADase, in accordance with some embodiments. Fig. 9A: Structure of isothiazole hit compound 1 identified as a weak inhibitor of ADPR production by NAD+ hy drolysis. Fig.

[0030] 9B: Core isothiazole structure subjected to structure-activity relationship studies. Fig. 9C: Structure-activity relationship of the isothiazoles.

[0031] DETAILED DESCRIPTION

[0032] The following disclosure provides many different embodiments, or examples, for implementing different features of the provided subject matter. Specific examples of components and arrangements are described below to simplify the present disclosure. These are, of course, merely examples and are not intended to be limiting. For example, the formation of a first feature over or on a second feature in the description that follows may include embodiments in which the first and second features are formed in direct contact, and may also include embodiments in which additional features may be formed between the first and second features, such that the first and second features may not be in direct contact. In addition, the present disclosure may repeat reference numerals and / or letters in the various examples. This repetition is for the purpose of simplicity and clarify and does not in itself dictate a relationship between the various embodiments and / or configurations discussed.

[0033] The present study discovered that protein depalmitoylation. such as the depalmitoylase activity in the axons, drives axonal degeneration, and the inhibition of such activity7is effective in the treating, ameliorating, and / or prevention of axon degeneration.

[0034] Accordingly, in some aspects, the present invention is directed to compositions and methods for treating, ameliorating, and / or preventing a disease or condition associated with axon degeneration in a subject in need, such as by modulating palmitoylation.

[0035] 4

[0036] 578220772Atorney Docket No. 394948-0104W01(00013)

[0037] The present study further discovered that sterile alpha and toll / interleukin- 1 receptor motif-containing 1 (SARM1) inhibition works in additive or synergistic with the depalmitoylation in treating, ameliorating, and / or preventing axon degradation.

[0038] Accordingly, the composition further comprises a SARM1 inhibitor, and the method further comprises inhibiting SARM1 in the subject.

[0039] Definitions

[0040] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary7skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, exemplary methods and materials are described.

[0041] As used herein and in the appended claims, the singular forms “a,” “or,” and "the' include plural referents unless the context clearly dictates otherwise.

[0042] “About” as used herein when referring to a measurable value such as an amount, a temporal duration, age, and the like, is meant to encompass variations of ±20%, ±10%. ±5%, ±1%, or ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.

[0043] The term “alkyl” as used herein refers to straight chain and branched alkyl groups and cycloalkyl groups having from 1 to 40 carbon atoms, 1 to about 20 carbon atoms, 1 to 12 carbons or, in some embodiments, from 1 to 8 carbon atoms. Examples of straight chain alky l groups include those with from 1 to 8 carbon atoms such as methyl, ethyl, n-propyl, n-butyl, n-penty l, n-hexyl, n-heptyl, and n-octyl groups. Examples of branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, sec-butyl, t-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups. As used herein, the term “alkyl” encompasses n-alkyl, isoalkyl, and anteisoalkyl groups as well as other branched chain forms of alky l.

[0044] The term “dysregulation” when used in the context of organisms, tissues, cells or components thereof, refers to those organisms, tissues, cells or components thereof that differ in at least one observable or detectable characteristic (e.g., age, treatment, time of day, and so forth) from those organisms, tissues, cells or components thereof that display the normally “regulated” (expected) respective characteristic. Characteristics which are regulated or expected for one cell or tissue type, might be dysregulated for a different cell or tissue type.

[0045] 5

[0046] 578220772Atorney Docket No. 394948-0104W01(00013)

[0047] A “disease"’ is a state of health of an animal wherein the animal cannot maintain homeostasis, and wherein if the disease is not ameliorated then the animal’s health continues to deteriorate.

[0048] In contrast, a “disorder” in an animal is a state of health in which the animal is able to maintain homeostasis, but in which the animal’s state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the animal’s state of health.

[0049] A disease or disorder is “alleviated” if the severity of a sign or symptom of the disease or disorder, the frequency with which such a sign or symptom is experienced by a patient, or both, is reduced.

[0050] The terms “halo,” “halogen,” or “halide” group, as used herein, by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.

[0051] The term “haloalkyl” group, as used herein, includes mono-halo alkyl groups, polyhalo alkyl groups wherein all halo atoms can be the same or different, and per-halo alkyl groups, wherein all hydrogen atoms are replaced by halogen atoms, such as fluoro. Examples of haloalkyl include trifluoromethyl, 1,1 -di chloroethyl, 1,2-dichloroethyl, l,3-dibromo-3,3-difluoropropyl, peril uorobutyl. and the like.

[0052] The terms “patient,” “subject,” “individual,"’ and the like are used interchangeably herein, and refer to any animal, or cells thereof whether in vitro or in situ, amenable to the methods described herein. In some embodiments, the patient, subject or individual is a mammal such as anon-primate (e.g., cows, pigs, horses, cats, dogs, rats, etc.) and a primate (e.g., monkey and human), most preferably a human. In some non-limiting embodiments, the patient, subject or individual is a human.

[0053] A “therapeutic” treatment is a treatment administered to a subject who exhibits signs or symptoms of a disease or disorder, for the purpose of diminishing or eliminating those signs or symptoms.

[0054] As used herein, “treating a disease or disorder” means reducing the severity and / or frequency with which a sign or symptom of the disease or disorder is experienced by a patient.

[0055] An “effective amount” or “therapeutically effective amount” of a compound is that amount of a compound which is sufficient to provide a beneficial effect to the subject to which the compound is administered. An “effective amount” of a delivery vehicle is that amount sufficient to effectively bind or deliver a compound.

[0056] 6

[0057] 578220772Atorney Docket No. 394948-0104W01(00013)

[0058] As used herein, the term “pharmaceutically acceptable” refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively non-toxic, i.e., the material may be administered to an individual without causing an undesirable biological effect or interacting in a deleterious manner with any of the components of the composition in which it is contained.

[0059] As used herein, the term “pharmaceutical composition” refers to a mixture of at least one compound useful within the invention with a pharmaceutically acceptable carrier. The pharmaceutical composition facilitates administration of the compound to a patient or subject. Multiple techniques of administering a compound exist in the art including, but not limited to, intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary, and topical administration.

[0060] As used herein, the term “pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition, or carrier, such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in earn ing or transporting a compound useful within the invention within or to the patient such that it may perform its intended function. Typically, such constructs are earned or transported from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible w ith the other ingredients of the formulation, including the compound useful within the invention, and not injurious to the patient. Some examples of materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as com starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations. As used herein, “pharmaceutically acceptable carrier” also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of the compound useful within the invention and are physiologically acceptable to the patient. Supplementary active compounds may also be incorporated into the compositions. The “pharmaceutically acceptable carrier” may further 7

[0061] 578220772Atorney Docket No. 394948-0104W01(00013)

[0062] include a pharmaceutically acceptable salt of the compound useful within the invention. Other additional ingredients that may be included in the pharmaceutical compositions used in the practice of the invention are known in the art and described, for example in Remington’s Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.

[0063] As used herein, the language “pharmaceutically acceptable salt” refers to a salt of the administered compound prepared from pharmaceutically acceptable non-toxic acids and bases, including inorganic acids, inorganic bases, organic acids, inorganic bases, solvates, hydrates, and clathrates thereof.

[0064] Suitable pharmaceutically acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid. Examples of inorganic acids include hydrochloric, hydrobromic, hydriodic, nitric, carbonic, sulfuric (including sulfate and hydrogen sulfate), and phosphoric acids (including hydrogen phosphate and dihydrogen phosphate). Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which include formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, malonic, saccharin, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, trifluoromethanesulfonic, 2-hydroxyethanesulfonic, p-toluenesulfonic. sulfanilic, cyclohexylaminosulfonic, stearic, alginic, -hy dr oxy butyric, salicylic, galactaric and galacturonic acid.

[0065] Suitable pharmaceutically acceptable base addition salts of compounds described herein include, for example, ammonium salts, metallic salts including alkali metal, alkaline earth metal and transition metal salts such as, for example, calcium, magnesium, potassium, sodium and zinc salts. Pharmaceutically acceptable base addition salts also include organic salts made from basic amines such as, for example, N,N’-dibenzylethylene-diamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts may be prepared from the corresponding compound by reacting, for example, the appropriate acid or base with the compound.

[0066] As used herein, the term “potency” refers to the dose needed to produce half the maximal response (ED50).

[0067] As used herein, the term “efficacy” refers to the maximal effect (Emax) achieved within an assav.

[0068] 8

[0069] 578220772Atorney Docket No. 394948-0104W01(00013)

[0070] By the term "modulating." as used herein, is meant mediating a detectable increase or decrease in the level of a response in a subject compared with the level of a response in the subject in the absence of a treatment or compound, and / or compared with the level of a response in an otherwise identical but untreated subject. The term encompasses perturbing and / or affecting a native signal or response thereby mediating a beneficial therapeutic response in a subject, preferably, a human.

[0071] The term “activate,” as used herein, means to induce or increase an activity or function, for example, about ten percent relative to a control value. Preferably, the activity is induced or increased by 50% compared to a control value, more preferably by 75%, and even more preferably by 95%. The term “activate,” as used herein, also means to increase a molecule, a reaction, an interaction, a gene, an mRNA, and / or a protein's expression, stability, function or activity by a measurable amount or to increase entirely. Activators are compounds that, e.g., bind to, partially or totally induce stimulation, increase, promote, induce activation, activate, sensitize, or up regulate a protein, a gene, and an mRNA stability, expression, function and activity, e.g., agonists.

[0072] The phrase “inhibit,” as used herein, means to reduce a molecule, a reaction, an interaction, a gene, an mRNA, and / or a protein’s expression, stability, function or activity by a measurable amount or to prevent entirely. Inhibitors are compounds that, e.g., bind to, partially or totally block stimulation, decrease, prevent, delay activation, inactivate, desensitize, or down regulate a protein, a gene, and an mRNA stability, expression, function and activity, e.g., antagonists. In some embodiments, the activity is suppressed or blocked by 10% compared to a control value. In some embodiments, the activity is suppressed or blocked by 50% compared to a control value. In some embodiments, the activity is suppressed or blocked by 75%. In some embodiments, the activity is suppressed or blocked by 95%.

[0073] Ranges: throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example.

[0074] 1, 2, 2.7, 3. 4, 5, 5.3. and 6. This applies regardless of the breadth of the range. Reference to “about” a value or parameter herein includes (and describes) variations that are directed to 9

[0075] 578220772Atorney Docket No. 394948-0104W01(00013)

[0076] that value or parameter per se. For example, description referring to "about X” includes description ofL‘X?’.

[0077] Compositions or Kits for Treating, Ameliorating, and / or Preventing Axon Degeneration or Associated Diseases / Conditions

[0078] In some aspects, the present invention is directed to a composition or a kit.

[0079] In some embodiments, the composition / kit is for treating, ameliorating, and / or preventing axon degradation in a subject in need thereof.

[0080] In some embodiments, the composition / kit is for treating, ameliorating, and / or preventing a disease or condition caused by or involves axon degradation in a subject in need thereof.

[0081] In some embodiments, the composition / kit comprises a modulator of one or more selected from the group consisting of acyl-protein thioesterase (APT)-l, APT2, a / hydrolase domain-containing (ABHD) enzy me 16A, ABHD17A, ABHD17B, and ABHD17C.

[0082] In some embodiments, the modulator is a compound that downregulates APT1. APT2, ABHD 16 A, ABHD17A. ABHD17B, or ABHD17C.

[0083] In some embodiments, the composition or kit further comprises a compound that downregulates sterile alpha and toll / interleukin-1 receptor motif-containing 1 (SARMl).

[0084] Non-limiting examples of such modulators or compound for downregulation include a chemical compound, a protein, a peptide, a peptidomimetic, an antibody, a ribozyme, a small molecule chemical compound, a nucleic acid, a vector, an antisense nucleic acid, siRNA, shRNA, and a guide RNA. Such modulators are further described elsewhere herein.

[0085] Methods of Treating, Ameliorating, and / or Preventing Axon Degeneration or Associated Diseases / Conditions

[0086] In some aspects, the present invention is directed to a method.

[0087] In some embodiments, the method is for treating, ameliorating, and / or preventing axon degradation in a subject in a subject in need thereof.

[0088] In some embodiments, the method is for treating, ameliorating, and / or preventing a disease or condition caused by or involves axon degradation in a subject in need thereof.

[0089] In some embodiments, the method comprises administering to the subj ect an effective amount of a modulator of APT1, APT2, ABHD16A, ABHD17A, ABHD17B, or ABHD17C, a compound that down regulates APT1, APT2, ABHD16A. ABHD17A, ABHD17B. or ABHD17C, or the composition or kits herein.

[0090] 10

[0091] 578220772Atorney Docket No. 394948-0104W01(00013)

[0092] In some embodiments, the compounds, compositions, and / or kits herein are administered before, at about the same time, and / or after the onset of the axon degradation and / or the associated disease / condition. In some embodiments, the two events are considered at about the same time if they are separated by about 30 minutes, about 1 hour, about 2 hours, about 4 hours, about 6 hours, about 12 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 1 week, or any ranges therebetween. One of ordinary skill in the art would understand that, in some situations, the onset of axon degradation and / or the associated disease / condition can be fairly accurately determined, such as in the case of chemotherapy-induced peripheral neuropathy (CIPN).

[0093] Disease / Conditions Associated with Axon Degeneration

[0094] Many diseases and conditions are caused by, encompasses, comprises, or involves axon degeneration.

[0095] In some embodiments, the disease / condition associated with axon degeneration is one or more selected from the group consisting of acute injury’, (Wallerian-like degeneration), inherited sensorimotor neuropathies (Charcot Marie Tooth Disease), diabetic peripheral neuropathy7(DPN), chemotherapy-induced peripheral neuropathy’ (CIPN), Parkinson’s Disease, Alzheimer’s Disease, and Amyotrophic Lateral Sclerosis.

[0096] Further non-limiting examples of diseases / condition treatable by the compounds, compositions, kits, and / or methods herein include Alzheimer’s disease (AD). Mild Cognitive Impairment (MCI), Parkinson’s disease (PD), Huntington’s disease (HD), prion-caused diseases, frontotemporal dementia (FTD), Lewy body dementia, vascular dementias, white matter disease, traumatic brain injury', post-traumatic stress, stroke, tauopathies, Down Syndrome, Amyotrophic Later Sclerosis (ALS). chronic traumatic encephalopathy (CTE), progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBGD), Pick’s disease, olivopontocerebellar atrophy (OPCA), senile dementia of the Alzheimer ty pe, progressive supranuclear palsy (Steel-Richardson-Olszewski), corticodentatonigral degeneration, Hallervorden-Spatz disease, striatonigral degeneration, torsion dystonia (e.g., torsion spasm; dystonia musculorum deformans), spasmodic torticollis and other dyskinesis, familial tremor, Gilles de la Tourette syndrome, cerebellar cortical degeneration, spinocerebellar degeneration (e.g., Friedreich’s ataxia and related disorders), Shy-Drager syndrome, spinal muscular atrophy, primary' lateral sclerosis, hereditary spastic paraplegia, peroneal muscular atrophy, hypertrophic interstitial polyneuropathy’ (Dejerine-Sottas), chronic progressive neuropathy, pigmentary' degeneration of the retina (retinitis 11

[0097] 578220772Atorney Docket No. 394948-0104W01(00013)

[0098] pigmentosa), hereditary' optic atrophy (Leber’s disease), Cognitive Dysfunction Syndrome, White dog shaker syndrome, degenerative myelopathy, neuroaxonal dystrophy, cerebellar degeneration, cerebellar abiotrophy, cerebral amyloid angiopathy (CAA), amyloid related imaging abnormalities (ARIA), traumatic glaucoma, demyelinating optic neuropathy (such as optic neuritis (ON) associated with Multiple Sclerosis (MS), MOGAD, and NMOSD).

[0099] Compounds that Downregulate APT1, APT2, ABHD16A, ABHD17 A, ABHD17B, ABHD17C, and / or SARM1

[0100] One of ordinary' skill in the art would understand that the strategies of downregulating APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 are known in the art. These targets can be downregulated at the genomic level, transcriptional level, translational level, post-translational level, or protein level.

[0101] In some embodiments, the compound that downregulates APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 acts at the genomic level. For example, the expression level of any of the targets can be downregulated by gene knockout, such as CRISPR knockout and other knockout techniques.

[0102] In some embodiments, the compound that downregulates APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 acts at the transcriptional level or the translational level. For example, the expression level of any of the targets can be downregulated by gene knockdown, such as by RNA interference technique, ribozyme knockdown, or CRISPR knockdown.

[0103] In some embodiments, the compound that downregulates APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 acts at the post-translational level. For example, the expression level of any of the targets can be downregulated by targeted protein degradation, such as proteolysis-targeting chimera (PROTAC) and other protein degradation strategies. For example, the activity of any of the targets here can be dow nregulated by small molecules inhibitors, neutralizing antibodies, or trans -dominant negative mutants.

[0104] In some embodiments, the compound that downregulates APT1, APT2. ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 includes a small molecule inhibitor of any of the targets, a protein inhibitor of any of the targets, or a compound that downregulates the expression level and / or activity' of any of the targets by RNA interference, by ribozyme, by CRISPR knockout / knockdown, or by producing a trans-dominant negative mutant, and so forth.

[0105] 12

[0106] 578220772Atorney Docket No. 394948-0104W01(00013)

[0107] In some embodiments, the compound contemplated herein can be delivered by a vector, such as a plasmid or a viral vector. One of ordinary skill in the art would understand that such vectors can be used to deliver compounds in the form of nucleic acids, such as RNA or DNA. Such vectors are described elsewhere herein.

[0108] In some embodiments, the compound contemplated herein (including but not limited to nucleic acids) can be more efficiently delivered to the cell nucleus by coupling the compound with the monoclonal anti-DNA antibody 3E10, which penetrates living cells and localizes in the nucleus without causing any apparent harm to the cell (Hansen JE, et al., Intranuclear protein transduction through a nucleoside salvage pathway. J Biol Chem 2007;282:20790-3; see also WO 2020 / 047353 and WO 2021 / 042060, all of which are incorporated herein in their entireties by reference). 3E10 and its single-chain variable fragment (3E10 scFv) have been developed as an intracellular delivery system for macromolecules. After localizing in the cell nucleus, 3E10 scFv is largely degraded within 4 hours, thus further minimizing any potential toxicity.

[0109] In some embodiments, the compounds contemplated herein (including but not limited to nucleic acids) can be more efficiently delivered to the central nervous system using certain lipid nanoparticle formulations known in the art, such as but not limited to those described in Cullis, P. R. et al., Molecular Therapy Vol. 25 No 7 July 2017. See also US20150165039 and WO 2014 / 008334, all of which are incorporated herein in their entireties by reference.

[0110] In some embodiments, the compounds contemplated herein can be more efficiently delivered to tissue by coupling with certain protein fragments, called "‘pHLIP” (pH (Low) Insertion Peptide), which allow for the cargo to accumulate in acidic environments within the body. In some embodiments, a polypeptide with a predominantly hydrophobic sequence long enough to span a membrane lipid bilayer as a transmembrane helix (TM) and comprising one or more dissociable groups inserts across a membrane spontaneously in a pH-dependent fashion placing one terminus inside cell. The polypeptide conjugated with various functional moieties delivers and accumulates them at cell membrane with low extracellular pH. The functional moiety conjugated with polypeptide terminus placed inside cell are translocated through the cell membrane in cytosol. The peptide and its variants or non-peptide analogs can be used to deliver therapeutic, prophylactic, diagnostic, imaging, gene regulation, cell regulation, or immunologic agents to or inside of cells in vitro or in vivo in tissue at low extracellular pH. See also US20080233107, WO2012 / 021790, US20120039990, US20120142042, US20150051153, US20150086617. and US20150191508, all of which are incorporated herein in their entireties by reference.

[0111] 13

[0112] 578220772Atorney Docket No. 394948-0104W01(00013)

[0113] Downregulating APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 by Small Molecule Inhibitors

[0114] In some embodiments, the compound that downregulates the APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 includes a small molecule that inhibits any of the targets. As used herein, the term “small molecule” refers to a molecule having a size of less than 2000, 1800, 1600, 1400, 1200, 1000, 800. or 600 Daltons.

[0115] Non-limiting examples of small molecule inhibitors for APT1 include HDFP, ML-211, ML348, Palmostatin B (PaltnB), Palmostatin M (PaltnM), and the like

[0116] Non-limiting examples of small molecule inhibitors for APT2 include HDFP, ML-211, ML349. PalmB, PalmM, and the like.

[0117] Non-limiting examples of small molecule inhibitors for ABHD16A include DH376, KC01, KT195, (Z)-KC02, and the like. Additional inhibitors for ABHD16A are described in, for example, Kamat et al. (Nat Chem Biol. 2015 Feb;ll(2):164-71. doi:

[0118] 10.1038 / nchembio.l721), all of which is incorporated herein in their entireties by reference.

[0119] Non-limiting examples of small molecule inhibitors for the ABHD17 family (ABHD17A, ABHD17B, and ABHD17C) include ABD778, ABD957, and the like.

[0120] The inhibitors of the ABHD family are also described in, for example, Bononi et al., (J Med Chem. 2021 Jul 2;64(14):9759-9785. doi: 10.1021 / acs.jmedchem. lc00624), all of which is incorporated herein in their entireties by reference.

[0121] Non-limiting examples of small molecule inhibitors for SARM1 include 5-chloroisoquinoline, berberine chloride, CZ-48 (Sulfo-ara-F-NMN), dHNN, dehydronitrosonisoldipine, DSRM-3716 (5-iodoisoquinoline), GNE-5152, hematoxylin, isoquinoline. NaMN (nicotinic acid mononucleotide). NB-3, NB-7. nicotinamide, phenazopyridine, phenazopyridine hydrochloride, RO-7529, SA91-0178, SIR2501, and zinc chloride. Additional inhibitors of SARM1 are described in, for example, WO 2019 / 236890 Al, WO 2024 / 126777 Al, WO 2025 / 049184 Al, Albanese et al. (J Med Chem. 2026 Apr 23;69(8):9521-9536. doi: 10.1021 / acs.jmedchem.6c00352). Beresis et al. (ACS Omega. 2025 Jul 31;10(31):34747-34761. doi: 10.1021 / acsomega.5c03734), Feldman et al. (Proc Natl Acad Sci U S A. 2022 Aug 30;l 19(35):e2208457119. doi: 10.1073 / pnas.2208457119), Giroud et al. (J Med Chem. 2025 Mar 27;68(6):6558-6575. doi:

[0122] 10.1021 / acs.jmedchem.4c03127), Green et al. (ACS Med Chem Lett. 2025 May 20:16(6): 1147-1154. doi: 10.1021 / acsmedchemlett.5c00189). Lundback et al. (bioRxiv 2025.11.11.687870; doi: https: / / doi.org / 10.1101 / 2025.l l.ll.687870), all of which are 14

[0123] 578220772Atorney Docket No. 394948-0104W01(00013)

[0124] incorporated herein in their entireties by reference. Further non-limiting embodiments of SARM1 inhibitors are exemplified in Figs. 9A-9C. Non-limiting embodiments of SARM1 inhibitors include a compound of formula (I):

[0125] N

[0126]

[0127] NHR1([).

[0128] wherein:

[0129] R1is phenyl, naphthyl, quinolinyl, or isoquinolinyl, any of which is optionally substituted with one or more optionally selected from the group consisting of C1-C3 alkyl, F, Cl, Br, I, Ci-C? haloalkyl, C1-C3 alkoxy. C1-C3 haloalkoxy, and -SO2(Ci-C3 alkyl);

[0130] R2is H or C1-C3 alkyl;

[0131] or a pharmaceutically acceptable salt. In certain embodiments, the naphthyl is naphth- 1-yl or naphtha-2 -yl. In certain embodiments, the quinolinyl is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl. quinolin-6-yl, quinolin-7-yl, or quinolin-8-yl. In certain embodiments, the isoquinolinyl is isoquinolin- 1-yl, isoquinolin-3-yl, isoquinolin-4-yl, isoquinolin-5-yl. isoquinolin-6-yl, isoquinolin-7-yl, or isoquinolin-8-yl.

[0132] In some embodiments, the small molecule inhibitor comprises a PROTAC or a Proteolysis Targeting Chimeric Molecule. PROTACs are heterobifunctional nanomolecules that can target any protein for ubiquitination and degradation. In some embodiments, the PROTAC contemplated in the present invention comprises a group that is recognized by the E3 ubiquitin ligase and a group that is recognized by APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1. The PROTAC can simultaneously bind to the targets and the E3 ligase. Formation of such trimeric complex formation leads to the transfer of ubiquitins to the targets, marking it for degradation. PROTAC molecules possess good tissue distribution and the ability' to target intracellular proteins, thus can be directly applied to cells or injected into animals without the use of vectors. PROTACS useful within the invention can be prepared using any known compound that binds to and / or recognizes and / or inhibits APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1, which is linked through a linker to an E3 ubiquitin ligase, such as but not limited to those described in WO 2013 / 106643, WO 2013 / 106646, and WO 2019 / 148055.

[0133] 15

[0134] 578220772Atorney Docket No. 394948-0104W01(00013)

[0135] Downregulating APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARMlby Antibodies

[0136] In some embodiments, the compound that downregulates APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 includes an antibody that downregulates any of the targets.

[0137] Non-limiting examples of monoclonal and / or polyclonal antibodies that target APT1 include F7H3F from Cell Signaling Technology (Danvers, MA, USA), 16055-1 -AP from Proteintech (Rosemont, IL, USA), and the like.

[0138] Non-limiting examples of monoclonal and / or polyclonal antibodies that target APT1 include MA5-30659 from Invitrogen (Carlsbad, CA, USA), sc-515061 from Santa Cruz Biotechnology (Dallas, TX, USA), and the like.

[0139] Non-limiting examples of monoclonal and / or polyclonal antibodies that target ABHD16A include EPR15463 from Abeam (Cambridge, UK), HPA058606 from Sigma-Aldrich (Burlington, MA, USA), and the like.

[0140] Non-limiting examples of monoclonal and / or polyclonal antibodies that target ABHD17A include PA5-140126 and PA5-46020 from Invitrogen (Carlsbad. CA, USA), and the like.

[0141] Non-limiting examples of monoclonal and / or polyclonal antibodies that target ABHD17B include HPA047862 from Sigma-Aldrich (Burlington, MA, USA), TA331704 from OriGene (Rockville, MD, USA), and the like.

[0142] Non-limiting examples of monoclonal and / or polyclonal antibodies that target ABHD17C include PA5-61831 from Invitrogen, HPA048890 from Sigma- Aldrich, and the like.

[0143] Non-limiting examples of monoclonal and / or polyclonal antibodies that target SARM1 include MABN2711 (Clone 10G2) from Sigma-Aldnch, 13022 (Clone D2M5I) from Cell Signaling Technology, and the like.

[0144] In some embodiments, the antibody that downregulates APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 is administered in form of a protein. In some embodiments, the antibody is administered in form of a nucleic acid that expresses the protein, such as an expression vector. The expression vector is described in the “Vector” section elsewhere herein.

[0145] Downregulating APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 by RNA Interference

[0146] 16

[0147] 578220772Atorney Docket No. 394948-0104W01(00013)

[0148] In some embodiments, the compound that downregulates the APT1, APT2, ABHD16A, ABHD17A. ABHD17B, ABHD17C, and / or SARM1 includes a nucleic acid that downregulates any of the targets by the means of RNA interference.

[0149] In some embodiments, the nucleic acid that downregulates the expression level of APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 by the means of RNA interference includes an isolated nucleic acid. In other embodiments, the modulator is an RNAi molecule (such as but not limited to siRNA and / or shRNA and / or miRNAs) or antisense molecule, which inhibits the expression and / or activity. In yet other embodiments, the nucleic acid comprises a promoter / regulatory sequence, such that the nucleic acid is preferably capable of directing expression of the nucleic acid. Thus, the present specification provides expression vectors and methods for the introduction of exogenous DNA into cells with concomitant expression of the exogenous DNA in the cells such as those described, for example, in Sambrook et al. (2012, Molecular Cloning: A Laboratory' Manual, Cold Spring Harbor Laboratory, New York), and in Ausubel et al. (1997, Current Protocols in Molecular Biology, John Wiley & Sons, New York) and as described elsewhere herein.

[0150] In some embodiments, siRNA is used to decrease the level of APTL APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1. RNA interference (RNAi) is a phenomenon in which the introduction of double-stranded RNA (dsRNA) into a diverse range of organisms and cell types causes degradation of the complementary mRNA. In the cell, long dsRNAs are cleaved into short 21-25 nucleotide small interfering RNAs. or siRNAs, by a ribonuclease known as Dicer. The siRNAs subsequently assemble with protein components into an RNA-induced silencing complex (RISC), unwinding in the process. Activated RISC then binds to complementary transcript by base pairing interactions betw een the siRNA antisense strand and the mRNA. The bound mRNA is cleaved and sequence specific degradation of mRNA results in gene silencing. See, for example, U.S. Patent No.

[0151] 6,506,559; Fire et al., 1998, Nature 391(19):306-311; Timmons et al., 1998, Nature 395:854; Montgomery et al., 1998, TIG 14 (7):255-258; Engelke, Ed., RNA Interference (RNAi) Nuts & Bolts of RNAi Technology, DNA Press, Eagleville, PA (2003); and Hannon, Ed., RNAi A Guide to Gene Silencing, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2003). Soutschek et al. (2004, Nature 432:173-178) describes a chemical modification to siRNAs that aids in intravenous systemic delivery'. Optimizing siRNAs involves consideration of overall G / C content, C / T content at the termini, Tm and the nucleotide content of the 3’ overhang. See, for instance, Schwartz et al., 2003. Cell, 115:199-208 and Khvorova et al. , 2003, Cell 115:209-216. Therefore, the present specification also includes 17

[0152] 578220772Atorney Docket No. 394948-0104W01(00013)

[0153] methods of decreasing levels of APT 1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 using RNAi technology.

[0154] In some embodiments, the present specification provides a vector comprising an siRNA or antisense polynucleotide. In other embodiments, the siRNA or antisense polynucleotide inhibits the expression of APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1. The incorporation of a desired polynucleotide into a vector and the choice of vectors is well-known in the art.

[0155] In some embodiments, the expression vectors described herein encode a short hairpin RNA (shRNA) inhibitor. shRNA inhibitors are well know n in the art and are directed against the mRNA of a target, thereby decreasing the expression of the target. In some embodiments, the encoded shRNA is expressed by a cell, and is then processed into siRNA. For example, in certain instances, the cell possesses native enzymes (e.g, dicer) that cleaves the shRNA to form siRNA.

[0156] The siRNA, shRNA, or antisense polynucleotide can be cloned into a number of types of vectors as described elsewhere herein. For expression of the siRNA or antisense polynucleotide, at least one module in each promoter functions to position the start site for RNA synthesis.

[0157] To assess the expression of the siRNA, shRNA, or antisense polynucleotide, the expression vector to be introduced into a cell can also contain either a selectable marker gene or a reporter gene or both to facilitate identification and selection of expressing cells from the population of cells sought to be transfected or infected using a viral vector. In some embodiments, the selectable marker may be carried on a separate piece of DNA and used in a co-transfection procedure. Both selectable markers and reporter genes may be flanked with appropriate regulatory sequences to enable expression in the host cells. Useful selectable markers are known in the art and include, for example, antibiotic-resistance genes, such as neomycin resistance and the like.

[0158] Following the generation of the siRNA polynucleotide, a skilled artisan will understand that the siRNA polynucleotide has certain characteristics that can be modified to improve the siRNA as a therapeutic compound. Therefore, in some embodiments, the siRNA polynucleotide is further designed to resist degradation by modifying it to include phosphorothioate, or other linkages, methylphosphonate, sulfone, sulfate, ketyl, phosphorodithioate, phosphoramidate, phosphate esters, and the like (see, e.g., Agrwal et al., 1987, Tetrahedron Lett. 28:3539-3542; Stec et al., 1985 Tetrahedron Lett. 26:2191-2194; Moody et al., 1989 Nucleic Acids Res. 12:4769-4782; Eckstein, 1989 Trends Biol. Sci.

[0159] 18

[0160] 578220772Atorney Docket No. 394948-0104W01(00013)

[0161] 14:97-100; Stein, In: Oligodeoxynucleotides. Antisense Inhibitors of Gene Expression, Cohen, ed.. Macmillan Press, London, pp. 97-117 (1989)).

[0162] Any polynucleotide may be further modified to increase its stability7in vivo. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5 ’ and / or 3’ ends; the use of phosphoro thioate or 2’ O-methyl rather than phosphodiester linkages in the backbone; and / or the inclusion of nontraditional bases such as inosine, queosine, and wybutosine and the like, as well as acetyl- methyl-, thio- and other modified forms of adenine, cytidine, guanine, thymine, and uridine.

[0163] In some embodiments, an antisense nucleic acid sequence expressed by a plasmid vector is used to inhibit the protein expression of APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1. The antisense expressing vector is used to transfect a mammalian cell or the mammal itself, thereby causing reduced endogenous expression of any of the targets.

[0164] Antisense molecules and their use for inhibiting gene expression are well known in the art (see, e.g., Cohen, 1989. In: Oligodeoxyribonucleotides, Antisense Inhibitors of Gene Expression, CRC Press). Antisense nucleic acids are DNA or RNA molecules that are complementary, as that term is defined elsewhere herein, to at least a portion of a specific mRNA molecule (Weintraub, 1990, Scientific American 262:40). In the cell, antisense nucleic acids hybridize to the corresponding mRNA, forming a double-stranded molecule thereby inhibiting the translation of genes.

[0165] The use of antisense methods to inhibit the translation of genes is known in the art, and is described, for example, in Marcus-Sakura (1988, Anal. Biochem. 172:289). Such antisense molecules may be provided to the cell via genetic expression using DNA encoding the antisense molecule as taught by Inoue. 1993, U.S. Patent No. 5.190,931.

[0166] Alternatively, antisense molecules of the present specification may be made synthetically and then provided to the cell. Antisense oligomers of between about 10 to about 30, and more preferably about 15 nucleotides, are preferred, since they are easily synthesized and introduced into a target cell. Synthetic antisense molecules contemplated by the present specification include oligonucleotide derivatives known in the art which have improved biological activity compared to unmodified oligonucleotides (see U.S. Patent No. 5,023,243).

[0167] Downregulating APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 by Ribozyme

[0168] 19

[0169] 578220772Atorney Docket No. 394948-0104W01(00013)

[0170] In some embodiments, the compound that down regulates the activity or expression level of APT1, APT2, ABHD16A, ABHD17A, ABHD17B. ABHD17C, and / or SARM1 includes a ribosome that inhibits the protein expression of any of the targets.

[0171] A ribozyme is used to inhibit APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 protein expression. Ribozymes useful for inhibiting the expression of a target molecule may be designed by incorporating target sequences into the basic ribozyme structure which are complementary, for example, to the mRNA sequence encoding the target proteins. Ribozymes are antisense RNAs which have a catalytic site capable of specifically cleaving complementary RNAs. Therefore, ribozy mes having sequence complementary to the mRNA sequences are capable of downregulating the expression of the target proteins by reducing the level of mRNA. Ribozymes targeting the proteins may be synthesized using commercially available reagents (Applied Biosystems, Inc., Foster City, CA) or they may be genetically expressed from DNA encoding them. In some embodiments, the DNA encoding the ribozymes are incorporated in a vector, which is described in the "‘Vector” section elsewhere herein.

[0172] Downregulating APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 by CRISPR Knockout / Knockdown and Other Knockouts / Knockdown Techniques

[0173] In some embodiments, the compound that downregulates the activity or expression level of APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 comprises a nucleic acid that down regulates the expression level of any of the target proteins by the means of CRISPR knockout.

[0174] In some embodiments, the compound downregulates the activity or expression level of APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 comprises a CRISPR / Cas9 system for knocking out any of the targets.

[0175] The CRISPR / Cas9 system is a facile and efficient system for inducing targeted genetic alterations. Target recognition by the Cas9 protein requires a “seed” sequence within the guide RNA (gRNA) and a conserved di -nucleotide containing protospacer adjacent motif (PAM) sequence upstream of the gRNA-binding region. The CRISPR / Cas9 system can thereby be engineered to cleave virtually any DNA sequence by redesigning the gRNA in cell lines (such as 293T cells), primary cells, and CAR T cells. The CRISPR / Cas9 system can simultaneously target multiple genomic loci by co-expressing a single Cas9 protein with two

[0176] 20

[0177] 578220772Atorney Docket No. 394948-0104W01(00013)

[0178] or more gRNAs, making this system uniquely suited for multiple gene editing or synergistic activation of target genes.

[0179] The Cas9 protein and guide RNA form a complex that identifies and cleaves target sequences. Cas9 is comprised of six domains: REC I, REC II, Bridge Helix, PAM interacting, HNH, and RuvC. The Reel domain binds the guide RNA, while the Bridge helix binds to target DNA. The HNH and RuvC domains are nuclease domains. Guide RNA is engineered to have a 5’ end that is complementary to the target DNA sequence. Upon binding of the guide RNA to the Cas9 protein, a conformational change occurs activating the protein. Once activated, Cas9 searches for target DNA by binding to sequences that match its protospacer adjacent motif (PAM) sequence. A PAM is a two or three nucleotide base sequence within one nucleotide downstream of the region complementary to the guide RNA. In one nonlimiting example, the PAM sequence is 5’-NGG-3’. When the Cas9 protein finds its target sequence with the appropriate PAM, it melts the bases upstream of the PAM and pairs them with the complementary region on the guide RNA. Then the RuvC and HNH nuclease domains cut the target DNA after the third nucleotide base upstream of the PAM.

[0180] One non-limiting example of a CRISPR / Cas system used to inhibit gene expression, CRISPRi, is described in U.S. Patent Appl. Publ. No. US20140068797. CRISPRi induces permanent gene disruption that utilizes the RNA-guided Cas9 endonuclease to introduce DNA double stranded breaks which trigger error-prone repair pathways to result in frame shift mutations. A catalytically dead Cas9 lacks endonuclease activity. When coexpressed with a guide RNA, a DNA recognition complex is generated that specifically interferes with transcriptional elongation, RNA polymerase binding, or transcription factor binding. This CRISPRi system efficiently represses expression of targeted genes.

[0181] CRISPR / Cas gene disruption occurs when a guide nucleic acid sequence specific for a target gene and a Cas endonuclease are introduced into a cell and form a complex that enables the Cas endonuclease to introduce a double strand break at the target gene. In some embodiments, the CRISPR / Cas system comprises an expression vector, such as, but not limited to, an pAd5F35-CRISPR vector. In other embodiments, the Cas expression vector induces expression of Cas9 endonuclease. Other endonucleases may also be used, including butnot limited to, T7, Cas3, Cas8a, Cas8b, CaslOd, Csel, Csyl, Csn2, Cas4, CaslO, Csm2, Cmr5, Fokl, other nucleases know n in the art, and any combinations thereof.

[0182] In some embodiments, inducing the Cas expression vector comprises exposing the cell to an agent that activates an inducible promoter in the Cas expression vector. In such embodiments, the Cas expression vector includes an inducible promoter, such as one that is 21

[0183] 578220772Atorney Docket No. 394948-0104W01(00013)

[0184] inducible by exposure to an antibiotic (e.g., by tetracycline or a derivative of tetracycline, for example doxycycline). However, it should be appreciated that other inducible promoters can be used. The inducing agent can be a selective condition (e.g., exposure to an agent, for example an antibiotic) that results in induction of the inducible promoter. This results in expression of the Cas expression vector.

[0185] In some embodiments, guide RNA(s) and Cas9 can be delivered to a cell as a ribonucleoprotein (RNP) complex. RNPs are comprised of purified Cas9 protein complexed with gRNA and are well known in the art to be efficiently delivered to multiple types of cells, including but not limited to neurons, stem cells and immune cells (Addgene, Cambridge, MA, Minis Bio LLC, Madison, WI).

[0186] The guide RNA is specific for a genomic region of interest and targets that region for Cas endonuclease-induced double strand breaks. The target sequence of the guide RNA sequence may be within a loci of a gene or within anon-coding region of the genome. In some embodiments, the guide nucleic acid sequence is at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 30, 31, 32. 33. 34. 35, 36, 37, 38, 39, 40 or more nucleotides in length.

[0187] Guide RNA (gRNA), also referred to as '‘short guide RNA” orc'sgRNA”, provides both targeting specificity7and scaffolding / binding ability7for the Cas9 nuclease. The gRNA can be a synthetic RNA composed of a targeting sequence and scaffold sequence derived from endogenous bacterial crRNA and tracrRNA. gRNA is used to target Cas9 to a specific genomic locus in genome engineering experiments. Guide RNAs can be designed using standard tools well known in the art.

[0188] In the context of formation of a CRISPR complex, “target sequence” refers to a sequence to which a guide sequence is designed to have some complementarity, where hybridization between a target sequence and a guide sequence promotes the formation of a CRISPR complex. Full complementarity7is not necessarily required, provided there is sufficient complementarity to cause hybridization and promote formation of a CRISPR complex. A target sequence may comprise any polynucleotide, such as DNA or RNA polynucleotides. In some embodiments, a target sequence is located in the nucleus or cytoplasm of a cell. In other embodiments, the target sequence may be within an organelle of a eukaryotic cell, for example, mitochondrion or nucleus. Typically, in the context of an endogenous CRISPR system, formation of a CRISPR complex (comprising a guide sequence hybridized to a target sequence and complexed with one or more Cas proteins) results in cleavage of one or both strands in or near (e.g., within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50

[0189] 22

[0190] 578220772Atorney Docket No. 394948-0104W01(00013)

[0191] or more base pairs) the target sequence. As with the target sequence, it is believed that complete complementarity is not needed, provided this is sufficient to be functional.

[0192] In some embodiments, one or more vectors driving expression of one or more elements of a CRISPR system are introduced into a host cell, such that expression of the elements of the CRISPR system direct formation of a CRISPR complex at one or more target sites. For example, a Cas enzyme, a guide sequence linked to a tracr-mate sequence, and a tracr sequence could each be operably linked to separate regulatory elements on separate vectors. Alternatively, two or more of the elements expressed from the same or different regulatory elements may be combined in a single vector, with one or more additional vectors providing any components of the CRISPR system not included in the first vector. CRISPR system elements that are combined in a single vector may be arranged in any suitable orientation, such as one element located 5’ with respect to (’‘upstream” of) or 3’ with respect to (’’downstream" of) a second element. The coding sequence of one element may be located on the same or opposite strand of the coding sequence of a second element, and oriented in the same or opposite direction. In some embodiments, a single promoter drives expression of a transcript encoding a CRISPR enzyme and one or more of the guide sequence, tracr mate sequence (optionally operably linked to the guide sequence), and a tracr sequence embedded within one or more intron sequences (e.g., each in a different intron, two or more in at least one intron, or all in a single intron).

[0193] In some embodiments, the CRISPR enzy me is part of a fusion protein comprising one or more heterologous protein domains (e g. about or more than about 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, or more domains in addition to the CRISPR enzyme). A CRISPR enzyme fusion protein may comprise any additional protein sequence, and optionally a linker sequence betw een any two domains. Examples of protein domains that may be fused to a CRISPR enzyme include, without limitation, epitope tags, reporter gene sequences, and protein domains having one or more of the following activities: methylase activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, RNA cleavage activity and nucleic acid binding activity. Additional domains that may form part of a fusion protein comprising a CRISPR enzyme are described in U.S. Patent Appl. Publ. No. US20110059502, incorporated herein by reference. In some embodiments, a tagged CRISPR enzy me is used to identify the location of a target sequence.

[0194] Conventional viral and non-viral based gene transfer methods can be used to introduce nucleic acids in mammalian and non-mammalian cells or target tissues. Such 23

[0195] 578220772Atorney Docket No. 394948-0104W01(00013)

[0196] methods can be used to administer nucleic acids encoding components of a CRISPR system to cells in culture, or in a host organism. Non-viral vector delivery systems include DNA plasmids, RNA (e.g., a transcript of a vector described herein), naked nucleic acid, and nucleic acid complexed with a delivery vehicle, such as a liposome. Viral vector deli\ erx systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell (Anderson, 1992, Science 256:808-813; and Yu, et al., 1994, Gene Therapy 1:13-26).

[0197] In some embodiments, the CRISPR / Cas is derived from a type II CRISPR / Cas system. In other embodiments, the CRISPR / Cas system is derived from a Cas9 protein. The Cas9 protein can be from Streptococcus pyogenes, Streptococcus thermophilus, or other species.

[0198] In general, Cas proteins comprise at least one RNA recognition and / or RNA binding domain. RNA recognition and / or RNA binding domains interact with the guiding RNA. Cas proteins can also comprise nuclease domains (i. e. , DNase or RNase domains), DNA binding domains, helicase domains, RNAse domains, protein-protein interaction domains, dimerization domains, as well as other domains. The Cas proteins can be modified to increase nucleic acid binding affinity and / or specificity', alter an enzymatic activity, and / or change another property7of the protein. In some embodiments, the Cas-like protein of the fusion protein can be derived from a wild type Cas9 protein or fragment thereof. In other embodiments, the Cas can be derived from modified Cas9 protein. For example, the amino acid sequence of the Cas9 protein can be modified to alter one or more properties (e.g., nuclease activity, affinity, stability, and so forth) of the protein. Alternatively, domains of the Cas9 protein not involved in RNA-guided cleavage can be eliminated from the protein such that the modified Cas9 protein is smaller than the wild type Cas9 protein. In general, a Cas9 protein comprises at least two nuclease (i.e., DNase) domains. For example, a Cas9 protein can comprise a RuvC-like nuclease domain and a HNH-like nuclease domain. The RuvC and HNH domains work together to cut single strands to make a double-stranded break in DNA. (Jinek, et al., 2012, Science, 337:816-821). In some embodiments, the Cas9-derived protein can be modified to contain only one functional nuclease domain (either a RuvC-like or a HNH-like nuclease domain). For example, the Cas9-derived protein can be modified such that one of the nuclease domains is deleted or mutated such that it is no longer functional (i.e., the nuclease activity is absent). In some embodiments in which one of the nuclease domains is inactive, the Cas9-derived protein is able to introduce a nick into a doublestranded nucleic acid (such protein is termed a “nickase”), but not cleave the double-stranded 24

[0199] 578220772Atorney Docket No. 394948-0104W01(00013)

[0200] DNA. In any of the above-described embodiments, any or all of the nuclease domains can be inactivated by one or more deletion mutations, insertion mutations, and / or substitution mutations using well-known methods, such as site-directed mutagenesis, PCR-mediated mutagenesis, and total gene synthesis, as well as other methods known in the art.

[0201] In some non-limiting embodiments, a vector drives the expression of the CRISPR system. The art is replete with suitable vectors that are useful in the present specification. The vectors to be used are suitable for replication and, optionally, integration in eukaryotic cells. Typical vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the desired nucleic acid sequence. The vectors of the present specification may also be used for nucleic acid standard gene delivery protocols. Methods for gene delivery are known in the art (U.S. Patent Nos. 5,399,346.

[0202] 5,580,859 & 5,589,466, incorporated by reference herein in their entireties).

[0203] Further, the vector may be provided to a cell in the form of a viral vector. Viral vector technology is w ell known in the art and is described, for example, in Sambrook et al. (4thEdition, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 2012), and in other virology and molecular biology manuals. Viruses, which are useful as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, Sindbis vims, gammaretrovirus and lentiviruses. In general, a suitable vector contains an origin of replication functional in at least one organism, a promoter sequence, convenient restriction endonuclease sites, and one or more selectable markers (e.g., WO 01 / 96584; WO 01 / 29058; and U.S. Patent No. 6,326,193).

[0204] In some embodiments, the compound that down regulates the activity' or expression level of APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 comprises a nucleic acid that down regulates the expression level of any of the targets by the means of CRISPR knockdown. CRISPR knockdown includes, but not limited to, CRISPRCasl3 knockdown. (See e.g., Mendez-Mancilla et al., Cell Chemical Biology 29, 1-7, 2021 Jul 27, and Kushawah et al., Dev Cell. 2020 Sep 28;54(6):805-817; the entireties of which are incorporated herein by reference).

[0205] In some embodiments, the present invention includes any other methods for effecting gene knockdown and / editing, which allow for deletion and / or inactivation of APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1, such as but not limited to those described in WO 2018 / 236840 (which is incorporated herein in its entirety by reference).

[0206] 25

[0207] 578220772Atorney Docket No. 394948-0104W01(00013)

[0208] Downregulating APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 by Inactivating and / or Sequestering

[0209] In some embodiments, the compound that downregulates the activity or expression level of APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 includes a protein that downregulates the activity7of any of the targets by inactivating and / or sequestering any of the targets. In some embodiments, the compound includes a nucleic acid that express the protein that downregulates the activity of APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 by inactivating and / or sequestering any of the targets. In some embodiments, the compound includes an expression vector that express the protein that downregulates the activity of APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 by inactivating and / or sequestering (see “Vector” section for descriptions on vectors).

[0210] In some embodiments, the compound that downregulates the expression level of APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 is a transdominant negative mutant of any of the targets, and / or a nucleic acid or a vector expressing the trans-dominant negative mutant of any of the targets.

[0211] Vectors

[0212] Vectors can increase the stability of the nucleic acids, make the delivery easier, or allow the expression of the nucleic acids or protein products thereof in the cells.

[0213] Therefore, in some embodiments, the protein inhibitors or the nucleic acids that dow nregulates the activity or expression level of APT1, APT2, ABHD16A, ABHD17A, ABHD17B, ABHD17C, and / or SARM1 is incorporated into a vector.

[0214] In some embodiments, the present specification relates to a vector, including the nucleic acid sequence of the present specification or the construct of the present specification. The choice of the vector will depend on the host cell in w hich it is to be subsequently introduced. In some embodiments, the vector of the present specification is an expression vector. Suitable host cells include a wide variety7of prokaryotic and eukaryotic host cells. In some embodiments, the expression vector is selected from the group consisting of a viral vector, a bacterial vector and a mammalian cell vector. Prokaryote- and / or eukaryote-vector based systems can be employed for use with the present specification to produce polynucleotide, or their cognate polypeptides. Many such systems are commercially and widely available.

[0215] 26

[0216] 578220772Atorney Docket No. 394948-0104W01(00013)

[0217] In some embodiments, the vector is a viral vector. Viral vector technology' is well known in the art and is described, for example, in virology and molecular biology manuals. Viruses, which are useful as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, and lentiviruses. In general, a suitable vector contains an origin of replication functional in at least one organism, a promoter sequence, convenient restriction endonuclease sites, and one or more selectable markers. (See. e.g., WO 01 / 96584; WO 01 / 29058; and U.S. Pat. No. 6.326,193.

[0218] In some embodiments, the viral vector is a suitable adeno-associated virus (AAV), such as the AAV1-AAV8 family of adeno-associated viruses. In some embodiments, the viral vector is a viral vector that can infect a human. The desired nucleic acid sequence, such as the nucleic acids that downregulates APT1, APT2, ABHD16A. ABHD17A, ABHD17B.

[0219] ABHD17C, and / or SARM1 described above, can be inserted between the inverted terminal repeats (ITRs) in the AAV. In various embodiments, the viral vector is an AAV2 or an AAV8. The promoter can be a thyroxine binding globulin (TBG) promoter. In various embodiments, the promoter is a human promoter sequence that enables the desired nucleic acid expression in the central nerves system (CNS), such as the brain, or the peripheral nerves system (PNS). In some embodiments, the promoter is a neuron-selective promoter or a neuron-specific promoter. The AAV can be a recombinant AAV, in which the capsid comes from one AAV serotype and the ITRs come from another AAV serotype. In various embodiments, the AAV capsid is selected from the group consisting of a AAV1, AAV2. AAV3, AAV4, AAV5, AAV6, AAV7, and a AAV8 capsid. In various embodiments, the ITR in the AAV is at least one ITR selected from the group consisting of a AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, and an AAV8 ITR. In various embodiments, the present specification contemplates an AAV8 viral vector (recombinant or non-recombinant) containing a desired nucleic acid expression sequence and at least one promoter sequence that, when administered to a subject, causes elevated systemic expression of the desired nucleic acid. In some embodiments, the viral vector is a recombinant or non-recombinant AAV2 or AAV5 containing any of the desired nucleic acid expression sequences described herein. In some embodiments, the AAV is an engineered AAV s for delivering nucleic acid across the blood brain barrier to the central and peripheral nervous systems, such as those as described by Chan et al., Nat Neurosci. 2017 Aug; 20(8): 1172-1179. The entirety of this reference is incorporated herein by reference.

[0220] In some embodiments, the vector in which the nucleic acid sequence is introduced is a plasmid that is or is not integrated in the genome of a host cell when it is introduced in the 27

[0221] 578220772Atorney Docket No. 394948-0104W01(00013)

[0222] cell. Illustrative, non-limiting examples of vectors in which the nucleotide sequence of the present specification or the gene construct of the present specification can be inserted include atet-on inducible vector for expression in eukaryote cells.

[0223] The vector may be obtained by conventional methods known by persons skilled in the art (Sambrook et al., 2012). In some embodiments, the vector is a vector useful for transforming animal cells.

[0224] In some embodiments, the recombinant expression vectors may also contain nucleic acid molecules which encode a peptide or peptidomimetic inhibitor of the present specification, described elsewhere herein.

[0225] A promoter may be one naturally associated with a gene or polynucleotide sequence, as may be obtained by isolating the 5' non-coding sequences located upstream of the coding segment and / or exon. Such a promoter can be referred to as “endogenous.” Similarly, an enhancer may be one naturally associated with a polynucleotide sequence, located either downstream or upstream of that sequence. Alternatively, certain advantages will be gained by positioning the coding polynucleotide segment under the control of a recombinant or heterologous promoter, which refers to a promoter that is not normally associated with a polynucleotide sequence in its natural environment. A recombinant or heterologous enhancer refers also to an enhancer not normally associated with a polynucleotide sequence in its natural environment. Such promoters or enhancers may include promoters or enhancers of other genes, and promoters or enhancers isolated from any other prokaryotic, viral, or eukaryotic cell, and promoters or enhancers not “naturally occurring,” i.e., containing different elements of different transcriptional regulatory regions, and / or mutations that alter expression. In addition to producing nucleic acid sequences of promoters and enhancers synthetically, sequences may be produced using recombinant cloning and / or nucleic acid amplification technology, including PCR™, in connection with the compositions disclosed herein (U.S. Patent 4,683,202, U.S. Patent 5,928,906). Furthermore, it is contemplated the control sequences that direct transcription and / or expression of sequences within non-nuclear organelles such as mitochondria, chloroplasts, and the like, can be employed as well.

[0226] It will be important to employ a promoter and / or enhancer that effectively directs the expression of the DNA segment in the cell type, organelle, and organism chosen for expression. Those of skill in the art of molecular biology generally know how' to use promoters, enhancers, and cell type combinations for protein expression. The promoters employed may be constitutive, tissue-specific, inducible, and / or useful under the appropriate

[0227] 28

[0228] 578220772Atorney Docket No. 394948-0104W01(00013)

[0229] conditions to direct high-level expression of the introduced DNA segment, such as is advantageous in the large-scale production of recombinant proteins and / or peptides. The promoter may be heterologous or endogenous.

[0230] The recombinant expression vectors may also contain a selectable marker gene which facilitates the selection of transformed or transfected host cells. Suitable selectable marker genes are genes encoding proteins such as G418 and hygromycin which confer resistance to certain drugs, P-galactosidase, chloramphenicol acetyltransferase, firefly luciferase, or an immunoglobulin or portion thereof such as the Fc portion of an immunoglobulin preferably IgG. The selectable markers may be introduced on a separate vector from the nucleic acid of interest.

[0231] Administration / Dosage / Formulations

[0232] The regimen of administration may affect what constitutes an effective amount. The therapeutic formulations contemplated within the disclosure may be administered to the subject either prior to or after the onset of a disease and / or disorder contemplated herein. Further, several divided dosages, as well as staggered dosages may be administered daily or sequentially, or the dose may be continuously infused, or may be a bolus injection. Further, the dosages of the therapeutic formulations contemplated w ithin the disclosure may be proportionally increased or decreased as indicated by the exigencies of the therapeutic or prophylactic situation.

[0233] Administration of the compositions contemplated within the disclosure to a patient, preferably a mammal, more preferably a human, may be carried out using known procedures, at dosages and for periods of time effective to treat a disease and / or disorder contemplated herein in the patient. An effective amount of the therapeutic compound necessary’ to achieve a therapeutic effect may vary according to factors such as the state of the disease or disorder in the patient; the age, sex, and weight of the patient; and the ability of the therapeutic compound contemplated w ithin the disclosure to treat a disease and / or disorder contemplated herein in the patient. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. A nonlimiting example of an effective dose range for a therapeutic compound contemplated w ithin the disclosure is from about 1 and 5,000 mg / kg of body weight / per day. One of ordinary skill in the art would be able to study the relevant factors and make the determination regarding the effective amount of the therapeutic compound w ithout undue experimentation.

[0234] 29

[0235] 578220772Atorney Docket No. 394948-0104W01(00013)

[0236] Actual dosage levels of the active ingredients in the pharmaceutical compositions contemplated within the disclosure may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

[0237] In particular, the selected dosage level depends upon a variety of factors including the activity of the particular compound employed, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds or materials used in combination with the compound, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well, known in the medical arts.

[0238] A medical doctor, e.g.. physician or veterinarian, having ordinary skill in the art may readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds contemplated within the disclosure employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

[0239] In particular embodiments, it is especially advantageous to formulate the compound in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the patients to be treated: each unit containing a predetermined quantity of therapeutic compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical vehicle. The dosage unit forms contemplated within the disclosure are dictated by and directly dependent on (a) the unique characteristics of the therapeutic compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding / formulating such a therapeutic compound for the treatment of a disease and / or disorder contemplated herein.

[0240] In some embodiments, the compositions of the disclosure are formulated using one or more pharmaceutically acceptable excipients or carriers. In some embodiments, the pharmaceutical compositions of the disclosure comprise a therapeutically effective amount of a compound of the disclosure and a pharmaceutically acceptable carrier.

[0241] The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the 30

[0242] 578220772Atorney Docket No. 394948-0104W01(00013)

[0243] required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms may be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it is preferable to include isotonic agents, for example, sugars, sodium chloride, or poly alcohols such as mannitol and sorbitol, in the composition. Prolonged absorption of the injectable compositions may be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate or gelatin.

[0244] In some embodiments, the compositions of the disclosure are administered to the patient in dosages that range from one to five times per day or more. In some embodiments, the compositions of the disclosure are administered to the patient in range of dosages that include, but are not limited to, once every day, every two. days, every three days to once a week, and once every two weeks. It is readily apparent to one skilled in the art that the frequency of administration of the various combination compositions of the disclosure varies from individual to individual depending on many factors including, but not limited to, age, disease or disorder to be treated, gender, overall health, and other factors. Thus, the disclosure should not be construed to be limited to any particular dosage regime and the precise dosage and composition to be administered to any patient is determined by the attending physical taking all other factors about the patient into account.

[0245] Compounds of the disclosure for administration may be in the range of from about 1 pg to about 10.000 mg, about 20 pg to about 9,500 mg, about 40 pg to about 9.000 mg, about 75 pg to about 8,500 mg, about 150 pg to about 7,500 mg, about 200 pg to about 7,000 mg, about 3050 pg to about 6,000 mg, about 500 pg to about 5,000 mg, about 750 pg to about 4,000 mg, about 1 mg to about 3,000 mg, about 10 mg to about 2,500 mg, about 20 mg to about 2,000 mg, about 25 mg to about 1,500 mg, about 30 mg to about 1.000 mg, about 40 mg to about 900 mg, about 50 mg to about 800 mg, about 60 mg to about 750 mg, about 70 mg to about 600 mg, about 80 mg to about 500 mg, and any and all whole or partial increments therebetween.

[0246] In some embodiments, the dose of a compound of the disclosure is from about 1 mg and about 2,500 mg. In some embodiments, a dose of a compound of the disclosure used in compositions described herein is less than about 10,000 mg, or less than about 8,000 mg, or less than about 6,000 mg, or less than about 5,000 mg, or less than about 3,000 mg, or less than about 2,000 mg, or less than about 1,000 mg, or less than about 500 mg, or less than about 200 mg, or less than about 50 mg. Similarly, in some embodiments, a dose of a second compound as described herein is less than about 1,000 mg, or less than about 800 mg, or less 31

[0247] 578220772Atorney Docket No. 394948-0104W01(00013)

[0248] than about 600 mg, or less than about 500 mg, or less than about 400 mg, or less than about 300 mg, or less than about 200 mg, or less than about 100 mg, or less than about 50 mg, or less than about 40 mg, or less than about 30 mg, or less than about 25 mg, or less than about 20 mg, or less than about 15 mg, or less than about 10 mg, or less than about 5 mg, or less than about 2 mg, or less than about 1 mg, or less than about 0.5 mg, and any and all whole or partial increments thereof.

[0249] In some embodiments, the present disclosure is directed to a packaged pharmaceutical composition comprising a container holding a therapeutically effective amount of a compound of the disclosure, alone or in combination with a second pharmaceutical agent; and instructions for using the compound to treat, prevent, or reduce one or more symptoms of axon degeneration or the associated diseases / conditions in a patient.

[0250] Formulations may be employed in admixtures with conventional excipients, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for intracranially, intrathecal , oral, parenteral, nasal, intravenous, subcutaneous, enteral, or any other suitable mode of administration, known to the art. The pharmaceutical preparations may be sterilized and if desired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure buffers, coloring, flavoring and / or aromatic substances and the like. They may also be combined where desired with other active agents, e.g., other analgesic agents.

[0251] Routes of administration of any of the compositions of the disclosure include oral, nasal, rectal, intravaginal, parenteral, buccal, sublingual or topical. The compounds for use in the disclosure may be formulated for administration by any suitable route, such as for oral or parenteral, for example, transdermal, transmucosal (e.g., sublingual, lingual, (trans)buccal, (trans)urethral, vaginal (e.g.. trans- and perivaginally), (intra)nasal and (trans)rectal). intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical administration.

[0252] Suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry powder or aerosolized formulations for inhalation, compositions and formulations for intravesical administration and the like. It should be understood that the formulations and compositions

[0253] 32

[0254] 578220772Atorney Docket No. 394948-0104W01(00013)

[0255] that would be useful in the present disclosure are not limited to the particular formulations and compositions that are described herein.

[0256] Oral Administration

[0257] For oral application, particularly suitable are tablets, dragees, liquids, drops, suppositories, or capsules, caplets and gelcaps. The compositions intended for oral use may be prepared according to any method known in the art and such compositions may contain one or more agents selected from the group consisting of inert, non-toxic pharmaceutically excipients that are suitable for the manufacture of tablets. Such excipients include, for example an inert diluent such as lactose: granulating and disintegrating agents such as cornstarch; binding agents such as starch; and lubricating agents such as magnesium stearate. The tablets may be uncoated or they may be coated by known techniques for elegance or to delay the release of the active ingredients. Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert diluent.

[0258] For oral administration, the compounds of the disclosure may be in the form of tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., polyvinylpyrrolidone, hydroxypropylcellulose or hydroxypropylmethylcellulose); fillers (e.g., cornstarch, lactose, microcrystal I inc cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc, or silica); disintegrates (e.g., sodium starch gly collate); or wetting agents (e.g., sodium lauryl sulphate). If desired, the tablets may be coated using suitable methods and coating materials such as OPADRY™ film coating systems available from Colorcon, West Point, Pa. (e.g., OPADRY™ OY Type, OYC Type, Organic Enteric OY -P Type, Aqueous Enteric OY -A Type, OY -PM Type and OPADRY™ White, 32K18400). Liquid preparation for oral administration may be in the form of solutions, syrups or suspensions. The liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agent (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl p-hydroxy benzoates or sorbic acid).

[0259] The present disclosure also includes a multi-layer tablet comprising a layer providing for the delayed release of one or more compounds of the disclosure, and a further layer providing for the immediate release of another medication. Using a wax / pH-sensitive polymer mix, a gastric insoluble composition may be obtained in which the active ingredient is entrapped, ensuring its delayed release.

[0260] 33

[0261] 578220772Atorney Docket No. 394948-0104W01(00013)

[0262] Parenteral Administration

[0263] For parenteral administration, the compounds of the disclosure may be formulated for injection or infusion, for example, intravenous, intramuscular or subcutaneous injection or infusion, or for administration in a bolus dose and / or continuous infusion. Suspensions, solutions or emulsions in an oily or aqueous vehicle, optionally containing other formulatory agents such as suspending, stabilizing and / or dispersing agents may be used.

[0264] Additional Administration Forms

[0265] Additional dosage forms of this disclosure include dosage forms as described in U.S. Patents Nos. 6.340,475; 6,488.962; 6,451.808; 5,972,389; 5,582,837; and 5,007,790.

[0266] Additional dosage forms of this disclosure also include dosage forms as described in U.S. Patent Applications Nos. 20030147952; 20030104062; 20030104053; 20030044466;

[0267] 20030039688; and 20020051820. Additional dosage forms of this disclosure also include dosage forms as described in PCT Applications Nos. WO 03 / 35041; WO 03 / 35040; WO 03 / 35029; WO 03 / 35177; WO 03 / 35039; WO 02 / 96404; WO 02 / 32416; WO 01 / 97783; WO 01 / 56544; WO 01 / 32217; WO 98 / 55107; WO 98 / 11879; WO 97 / 47285; WO 93 / 18755; and WO 90 / 11757.

[0268] Controlled Release Formulations and Drug Delivery Systems

[0269] In some embodiments, the formulations of the present disclosure may be, but are not limited to, short-term, rapid-offset, as well as controlled, for example, sustained release, delayed release and pulsatile release formulations.

[0270] The term sustained release is used in its conventional sense to refer to a drug formulation that provides for gradual release of a drug over an extended period of time, and that may, although not necessarily, result in substantially constant blood levels of a drug over an extended time period. The period of time may be as long as a month or more and should be a release which is longer that the same amount of agent administered in bolus form.

[0271] For sustained release, the compounds may be formulated with a suitable polymer or hydrophobic material which provides sustained release properties to the compounds. As such, the compounds for use the method of the disclosure may be administered in the form of microparticles, for example, by injection or in the form of wafers or discs by implantation.

[0272] 34

[0273] 578220772Atorney Docket No. 394948-0104W01(00013)

[0274] In some embodiments of the disclosure, the compounds of the disclosure are administered to a patient, alone or in combination with another pharmaceutical agent, using a sustained release formulation.

[0275] The term delayed release is used herein in its conventional sense to refer to a drug formulation that provides for an initial release of the drug after some delay following drug administration and that mat, although not necessarily, includes a delay of from about 10 minutes up to about 12 hours.

[0276] The term pulsatile release is used herein in its conventional sense to refer to a drug formulation that provides release of the drug in such a way as to produce pulsed plasma profiles of the drug after drug administration.

[0277] The term immediate release is used in its conventional sense to refer to a drug formulation that provides for release of the drug immediately after drug administration.

[0278] As used herein, short-term refers to any period of time up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes and any or all whole or partial increments thereof after drug administration after drug administration.

[0279] As used herein, rapid-offset refers to any period of time up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes, and any and all whole or partial increments thereof after drug administration.

[0280] Dosing

[0281] The therapeutically effective amount or dose of a compound of the present disclosure depends on the age, sex and weight of the patient, the current medical condition of the patient and the progression of the axon degeneration or associated disease / condition in the patient being treated. The skilled artisan is able to determine appropriate dosages depending on these and other factors.

[0282] A suitable dose of a compound of the present disclosure may be in the range of from about 0.01 mg to about 5,000 mg per day, such as from about 0.1 mg to about 1,000 mg, for example, from about 1 mg to about 500 mg, such as about 5 mg to about 250 mg per day. The dose may be administered in a single dosage or in multiple dosages, for example from 1 to 4 or more times per day. When multiple dosages are used, the amount of each dosage may be the same or different. For example, a dose of 1 mg per day may be administered as two 0.5 mg doses, with about a 12-hour interval between doses.

[0283] 35

[0284] 578220772Atorney Docket No. 394948-0104W01(00013)

[0285] It is understood that the amount of compound dosed per day may be administered, in non-limiting examples, every day. every other day, every 2 days, every 3 days, every 4 days, or every 5 days. For example, with every other day administration, a 5 mg per day dose may be initiated on Monday with a first subsequent 5 mg per day dose administered on Wednesday, a second subsequent 5 mg per day dose administered on Friday, and so on.

[0286] In the case wherein the patient’s status does improve, upon the doctor’s discretion the administration of the modulator of the disclosure is optionally given continuously; alternatively, the dose of drug being administered is temporarily reduced or temporarily suspended for a certain length of time (i.e., a “drug holiday’’). The length of the drug holiday optionally varies between 2 days and 1 year, including by way of example only, 2 days, 3 days. 4 days. 5 days. 6 days, 7 days, 10 days, 12 days. 15 days, 20 days, 28 days. 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or 365 days. The dose reduction during a drug holiday includes from 10%-100%, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%. 70%, 75%. 80%. 85%. 90%. 95%. or 100%.

[0287] Once improvement of the patient’s conditions has occurred, a maintenance dose is administered if necessary. Subsequently, the dosage or the frequency of administration, or both, is reduced, as a function of the patient’s condition, to a level at which the improved disease is retained. In some embodiments, patients require intermittent treatment on a longterm basis upon any recurrence of symptoms and / or infection.

[0288] The compounds for use in the method of the disclosure may be formulated in unit dosage form. The term “unit dosage form” refers to physically discrete units suitable as unitary dosage for patients undergoing treatment, with each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, optionally in association with a suitable pharmaceutical carrier. The unit dosage form may be for a single daily dose or one of multiple daily doses (e.g., about 1 to 4 or more times per day). When multiple daily doses are used, the unit dosage form may be the same or different for each dose.

[0289] Toxicity and therapeutic efficacy of such therapeutic regimens are optionally determined in cell cultures or experimental animals, including, but not limited to, the determination of the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between the toxic and therapeutic effects is the therapeutic index, which is expressed as the ratio between LD50 and ED50. Capsid assembly modulators exhibiting high therapeutic indices are preferred. The 36

[0290] 578220772Atorney Docket No. 394948-0104W01(00013)

[0291] data obtained from cell culture assays and animal studies are optionally used in formulating a range of dosage for use in human. The dosage of such capsid assembly modulators lies preferably within a range of circulating concentrations that include the ED50 with minimal toxicity. The dosage optionally varies within this range depending upon the dosage form employed and the route of administration utilized.

[0292] Those skilled in the art recognizes, or is able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures, embodiments, claims, and examples described herein. Such equivalents were considered to be within the scope of this disclosure and covered by the claims appended hereto. For example, it should be understood, that modifications in assay and / or reaction conditions, with art-recognized alternatives and using no more than routine experimentation, are within the scope of the present application.

[0293] It is to be understood that wherever values and ranges are provided herein, all values and ranges encompassed by these values and ranges, are meant to be encompassed within the scope of the present disclosure. Moreover, all values that fall within these ranges, as well as the upper or lower limits of a range of values, are also contemplated by the present application.

[0294] Examples

[0295] The invention is further described in detail by reference to the following experimental examples. These examples are provided for purposes of illustration only and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following examples, but rather, should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.

[0296] Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the present invention and practice the claimed methods. The following working examples thus specifically point out certain embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.

[0297] Example 1: Roles of protein depalmitoylation in distal axon degeneration

[0298] The cellular roles of depalmitoylase enzymes and their substrates that control degeneration of damaged axons are defined. Axon degeneration is a hallmark of diverse neuropathological conditions. After acute injury, axons degenerate via an active process known as Wallerian degeneration (WD). Similar ‘’Wallerian-like” degeneration is seen in 37

[0299] 578220772Atorney Docket No. 394948-0104W01(00013)

[0300] chronic peripheral neuropathies. A better understanding of axo-degenerative mechanisms could thus reveal new strategies to ameliorate a range of neuropathologies.

[0301] Current models of axon degeneration emphasize key roles for axon survival factors, labile proteins whose continuous transport from neuronal cell bodies supports distal axon integrity7. This anterograde supply is disrupted post-injury and in neuropathies and rapid degradation of remaining survival factors in distal axons drives axon degeneration. In particular, loss of the key survival factor, nicotinamide mononucleotide adenylyl transferase-2 (NMNAT2) activates the ‘axon executioner’ Sterile alpha and toll / interleukin-1 receptor motif-containing 1 (SARM1). Prolonged SARM1 activation is posited to trigger an irreversible ‘commitment to degenerate'.

[0302] Several proteins that regulate axon integrity and degeneration, including NMNAT2, are modified with the lipid palmitate, but how palmitoylation impacts the levels and / or activity7of these proteins, and hence the balance between axon integrity7and degeneration, is largely unknown. It is determined whether changes in this balance might take advantage of the unique reversibility7of palmitoylation compared to other protein-lipid modifications. Without being bound by a particular theory, it is hypothesized that acute depalmitoylation of specific axonal proteins is critical for axon degeneration. Consistent with this notion, it was found that treating cultured dorsal root ganglion (DRG) neurons, a cell ty pe widely used in WD studies, with Palmostatin B (PalmB, an inhibitor of several a / b hydrolase domain (ABHD)-family depalmitoylases). markedly protected axons after acute injury and in a model of chemotherapy-induced peripheral neuropathy (CIPN). PalmB also delayed axotomy-induced calcium influx and loss of mitochondrial membrane potential (A m), two events that precede physical axon degeneration. Importantly, a cocktail of four more selective inhibitors of specific ABHD depalmitoylases (‘4i’) afforded axon protection approaching that of PalmB. Unexpectedly, though, axon protection by depalmitoylase inhibitors was NMNAT2-and S ARM 1 -independent. These findings suggest that axonal depalmitoylase activity7drives axon degeneration via a previously unrecognized mechanism.

[0303] Example 2: Determination of protein depalmitoylation in distal axon degeneration Axon degeneration is a hallmark of diverse neuropathological conditions. After acute injury', axons degenerate via an active process known as Wallerian degeneration (WD). Mechanistically similar “Wallerian-like’’ degeneration is seen in chronic neuropathies, including Diabetic Peripheral Neuropathy (DPN, the most common chronic complication of diabetesjand chemotherapy -induced peripheral neuropathy (CIPN, a frequent side-effect of 38

[0304] 578220772Atorney Docket No. 394948-0104W01(00013)

[0305] chemotherapy) A beter understanding of axo-degenerative mechanisms could reveal new therapeutic strategies to preserve axon integrity and thereby ameliorate a range of neuropathologies.

[0306] Recent research has identified a key pathway that drives axon degeneration across diverse neuron types. Degeneration is triggered by depletion of the “axon survival factor”, nicotinamide mononucleotide adenylyl transferase-2 (NMNAT2), a labile protein whose continuous transport from neuronal cell bodies to distal axons normally ensures axon integrity. Damage to axons after acute injury and in chronic neuropathies disrupts such transport, and rapid degradation of remaining NMNAT2 in distal axons is a key trigger for axon degeneration. NMNAT2 consumes the biomolecule nicotinamide mononucleotide (NMN), generating nicotinamide adenine dinucleotide (NAD+). NMNAT2 loss elevates the axonal NMN:NAD+ ratio, which in turn activates the axonal 'executioner’ enzyme Sterile alpha and toll / interleukin-1 receptor motif-containing 1 (SARM1). SARM1 is anNADase that rapidly depletes remaining axonal NAD+, triggering a cascade of dow nstream events, including axonal ATP loss, mitochondrial membrane depolarization (A m loss), and an influx of extracellular calcium that is predictive of, and critical for, phenotypic degeneration (Fig. 1). This model is largely drawn from studies of acute, injury -induced degener-ation of axons of mammalian dorsal root ganglion (DRG) sensory' neurons, a cell type highly relevant to studies of nerve injury and neuropathy. Many elements of this model, particularly the critical role of the NMNAT2-SARM1 axis, are conserved across a range of peripheral and central mammalian neurons, and key elements of the pathway are evolutionarily conserved.

[0307] Most research into mechanisms of injury -induced WD is not driven by a goal of protecting severed axons from degeneration. Instead, WD is largely used as a ‘clean' model to gain insights into mechanisms that drive additional forms of axon degeneration in which other factors (most obviously a prolonged and / or asynchronous time course of degeneration, as often occurs in neuropathy) can complicate analysis. Consistent with this view, SARMl’s central role in WD has spurred intense interest in developing SARM1 inhibitors to ameliorate several forms of peripheral neuropathy and other conditions for which axon degeneration is a hallmark. However, despite its undoubted importance in many situations, SARM1 loss is only partially protective in some models of axonal injury and neuropathy, and axon degeneration in other neuropathological models is S ARM 1 -independent. These findings suggest the existence of parallel or additional axo-degenerative pathw ays.

[0308] In considering such pathways, it was noted that several proteins that control the balance between axonal integrity and degeneration are modified by palmitoylation. This 39

[0309] 578220772Atorney Docket No. 394948-0104W01(00013)

[0310] process refers to the covalent modification of specific cysteine residues with palmitate (Cl 6) or related fatty acids, and is sometimes termed S-acylation, or S-palmitoylation (Fig. 2). For simplicity the term ‘palmitoylation’ is used herein. Axonal palmitoyl -proteins include NMNAT2 itself, other survival factors of the stathmin (STMN) family, in particular STMN2 and STMN3, as well as dual leucine-zipper kinase (DLK), and DLK’s downstream target c-Jun N-terminal kinase-3 (JNK3). DLK and JNK3 act in proximal axons to convey retrograde signals to the neuronal soma but are also important for distal WD. At the cellular level, palmitoylation targets NMNAT2, STMN2 / 3, DLK and JNK3 to axonal vesicles, but palmitoylation can also target proteins to other specific membranes, most notably the plasma membrane.

[0311] Importantly, other lipid modifications including myristoylation (Cl 4) and prenylation (C15, C20 isoprenoid) can also target proteins to membranes. In considering why palmitoylation might have emerged as the key modifier of several regulators of axon integrity7, it was noted that palmitoylation is the only reversible protein-lipid modification. Palmitate is added to target proteins by protein acyltransferases (PATs) and removed by a / p hydrolase domain-containing (ABHD) enzymes (Fig. 2). This reversibility is important in other biological contexts, and several ABHD depalmitoylases are highly expressed in neurons. However, only isolated reports address roles of reversible palmitoylation in axons, and whether ABHD-mediated depalmitoylation of axonal proteins is necessary for WD and / or other forms of axon degeneration is completely unexplored.

[0312] The following sets of experiments 1) define the importance of specific depalmitoylases for different steps of the axo-degenerative process and comprehensively define the axonal substrates of each of these enzymes; and 2) determine the importance of axonal depalmitoylation for diverse forms of SARM1 -dependent and -independent axon degeneration.

[0313] Axonal depalmitoylase activity is essential for axon degeneration Palmitoylation is reversible and numerous regulators of axon integrity7are palmitoylated, but whether depalmitoylation is required for WD is unknown. Addressing this question required selective imaging and harvesting of axons, so DRG neuron ‘spot’ cultures, in which axons grow7outw ard from dissociated cell bodies plated in the center of a well, w ere optimized (Fig. 3A). After DRG axons were selectively injured with a biopsy punch, addition of the broad-spectrum depalmitoylase inhibitor Palmostatin B (PalmB) was highly axo-protective (Figs. 3B-3C). PalmB was added after axons were severed, suggesting that the 40

[0314] 578220772Atorney Docket No. 394948-0104W01(00013)

[0315] depalmitoylation event(s) blocked by PalmB must occur in axons i.e. that axonal depalmitoylase activity’ is essential for WD. PalmB also protected axons from Wallerian-like degeneration induced by the chemotherapeutic drug vincristine (Figs. 3D-3E). Axonal depalmitoylase activity' is thus required for multiple forms of axon degeneration.

[0316] To identify depalmitoylases that might account for PalmB-mediated axon protection, distal axonal fractions from DRG spot cultures were first harvested. These fractions were subjected to label-free, bottom-up proteomics using tryptic digest and liquid chromatography -tandem mass spectrometry' (LC-MS / MS). Taw files were processed using MaxQuant; peaks were searched against the UniProt rat database with the integrated Andromeda search tool; and MS intensities were quantified and normalized. Statistical analyses using Perseus identified a subset of ABHD family enzymes with reported protein depalmitoylase activity in axonal fractions, in particular Lysophospholipases-1 and -2 (LYPLA1, LYPLA2, also known as acyl-protein thioesterases-1- and -2 (APT1, 2) as well as ABHD16A, 17A, 17B and 17C (Fig. 4A). PalmB was developed as an APT1 inhibitor but inhibits other ABHD enzy mes, including all of the axonal ABHD depalmitoylases identified.

[0317] Consistent with an axo-degenerative role for these enzymes, combined inhibition of APT1, APT2, ABHD16A and ABHD17A-C (using the compounds ML348, ML349, KC01 and ABD957, all of which are structurally unrelated to PalmB) protected axons almost as effectively as did PalmB (Figs. 4B-4C). The similar effects of PalmB and this combined ML348 / ML349 / KC01 / ABD957 (‘4i’) treatment increases the likelihood that axon protection by these compounds is due to their inhibition of axonal depalmitoylase(s).

[0318] It was next determined how PalmB / 4i-mediated axon protection relates to the best known axo-degenerative pathway driven by NMNAT2 loss and subsequent SARM1 activation. Surprisingly, PalmB only minimally affected NMNAT2 loss post-injury’ (Fig. 5A). This finding in turn suggested that depalmitoylase inhibition might not prevent injury-induced SARM1 activation. A fluorescent probe that detects SARM1 activity' (AD- la) confirmed injury -induced SARM1 activation. SARM1 was still partially activated in PalmB-treated axons and, remarkably, was fully active in 4i-treated axons (Figs. 5B-5C). A SARM1 inhibitor (DSRM-3716, here termed ‘SARMli’) reduced AD-la signal to control (pre-injury) levels, confirming the validity of the readout (Figs. 5B-5C). This result indicates that 4i can still protect axons containing fully active SARM1, even though SARM1 activation has been posited to represent an irreversible ‘commitment to degenerate.’

[0319] To further test whether SARM1 and depalmitoylases control separate pro-degenerative pathways, it was determined if combinations of SARMli and PalmB / 4i 41

[0320] 578220772Atorney Docket No. 394948-0104W01(00013)

[0321] additively protect axons. PalrnB and 4i protected axons for 8-16 hrs (based on a semiautomated ‘axon degeneration index', with a value of 0.3 representing the boundary between intact and degenerated axons)(Fig. 5D, E). SARMli protected axons for 24-28 hrs.

[0322] Importantly, combining SARMli with either PalrnB or 4i protected axons for >40 hrs (Fig.

[0323] 5D, E). Also, although PalrnB was more axo-protective than 4i in isolation, protection by SARMli / PalmB and SARMli / 4i was very’ similar (Figs. 5D-5E). Together with the SARM1 activity probe results, these findings suggest that PalmB-mediated axon protection is partly’, but not fully, SARM1 -independent, while protection by the more specific 4i treatment is fully SARM1 -independent. In pilot studies (n=2 cultures, not shown), PalrnB and 4i also extended the protective effect of SARMli against vincristine-induced degeneration. Together, these findings suggest that axonal depalmitoylases control WD and Wallerian-like degeneration via a novel, S ARM 1 -independent pathway.

[0324] It was next determined if axonal depalmitoylases govern key events between initial injury’ and phenot pic WD. PalrnB prevented injur -induced A'Pm loss (monitored with TMRM dye) and cytosolic calcium elevation (monitored using a virally-delivered, axonally-targeted form of the genetically-encoded calcium indicator GCamP6m)(Figs. 6A-6D). These findings suggest that axonal depalmitoylase(s) act upstream of these events.

[0325] Notably, referring to Fig. 8, the axon protection effects of SARM1 inhibition and depalmitoylation inhibition are either additive or even synergistic.

[0326] ENUMERATED EMBODIMENTS

[0327] In some aspects, the present invention is directed to the following non-limiting embodiments:

[0328] Embodiment 1. A method of treating, ameliorating, and / or preventing axon degeneration or an associated disease or condition in a subject in need thereof, the method comprising administering to the subject a modulator of one or more selected from the group consisting of acyl-protein thioesterase (APT)-l, APT2, a / hydrolase domain-containing (ABHD) enzyme 16A, ABHD17A, ABHD17B, and ABHD17C,

[0329] Embodiment 2. The method of Embodiment 1, wherein the modulator is a compound that downregulates APT1, APT2, ABHD16A. ABHD17A, ABHD17B. and / or ABHD17C.

[0330] Embodiment 3. The method of any one of Embodiments 1-2, wherein the modulator is a compound that downregulates APT1, APT2, ABHD16A, ABHD17A, ABHD17B, and / or ABHD17C, and comprises at least one selected from the group consisting of:

[0331] 42

[0332] 578220772Atorney Docket No. 394948-0104W01(00013)

[0333] a small molecule inhibitor of APT 1, APT2, ABHD16A, ABHD17A, ABHD17B, and / or ABHD17C.

[0334] an antibody for APT1, APT2, ABHD16A, ABHD17A, ABHD17B, and / or ABHD17C,

[0335] anucleic acid that downregulates APT1, APT2, ABHD16A, ABHD17A, ABHD17B, and / or ABHD17C by RNA interference, and / or an expression vector expressing the same, a ribozyme that downregulates APT1, APT2, ABHD16A, ABHD17A, ABHD17B, and / or ABHD17C, and / or an expression vector expressing the same,

[0336] an expression vector comprising an expression cassette, wherein the expression cassette expresses CRISPR components that downregulate APT1, APT2, ABHD16A, ABHD17A, ABHD17B. and / or ABHD17C by CRISPR knockout or CRISPR knockdown, and

[0337] a trans-dominant negative mutant protein of APT1, APT2, ABHD16A, ABHD17A, ABHD17B, and / or ABHD17C, and / or an expression vector that expresses the same.

[0338] Embodiment 4. The method of any one of Embodiments 1-3, wherein at least one of the following applies:

[0339] (a) the modulator is a compound that downregulates APT1, and the compound is HDFP, ML-211, ML348, Palmostatin B (PalmB), and / or Palmostatin M (PalmM);

[0340] (b) the modulator is a compound that downregulates APT2, and the compound is HDFP. ML-211, ML349, PalmB, and / or PalmM;

[0341] (c) the modulator is a compound that downregulates ABHD16A, and the compound is DH376, KC01, KT195, and / or (Z)-KC02

[0342] (d) the modulator is a compound that downregulates ABHD17A, ABHD17B, and / or ABHD17C, and the compound is ABD778 and / or ABD957.

[0343] Embodiment 5. The method of any one of Embodiments 1-4, further comprising administering to the subject an effective amount of a compound that downregulates sterile alpha and toll / interleukin-1 receptor motif-containing 1 (SARM1).

[0344] Embodiment 6. The method of Embodiment 5, wherein the compound that downregulates SARM1 comprises at least one selected from the group consisting of:

[0345] a small molecule inhibitor of SARM1,

[0346] an antibody for SARM1,

[0347] anucleic acid that downregulates SARM1 by RNA interference, and / or an expression vector expressing the same,

[0348] 43

[0349] 578220772Atorney Docket No. 394948-0104W01(00013)

[0350] a ribozyme that downregulates SARM1, and / or an expression vector expressing the same,

[0351] an expression vector comprising an expression cassette, wherein the expression cassette expresses CRISPR components that downregulate SARM1 by CRISPR knockout or CRISPR knockdown, and

[0352] a trans-dominant negative mutant protein of SARM1, and / or an expression vector that expresses the same.

[0353] Embodiment 7. The method of any one of Embodiments 5-6, w herein the compound that that downregulates SARM1 comprises 5 -chloroisoquinoline, berberine chloride, CZ-48 (Sulfo-ara-F-NMN), dHNN, dehydronitrosonisoldipine. DSRM-3716 (5-iodoisoquinoline), GNE-5152, hematoxylin, isoquinoline, NaMN (nicotinic acid mononucleotide), NB-3. NB-7, nicotinamide, phenazopyridine, phenazopyridine hydrochloride, RO-7529, SA91-0178, SIR2501, zinc chloride, or a compound of formula (I):

[0354] O CN

[0355]

[0356] (I),

[0357] wherein:

[0358] R1is phenyl, naphthyl, quinolinyl, or isoquinolinyl, any of which is optionally substituted with one or more optionally selected from the group consisting of C1-C3 alkyl, F, Cl, Br, I, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, and -SO2(Ci-C3 alkyl);

[0359] R2is H or C1-C3 alkyl;

[0360] or a pharmaceutically acceptable salt thereof.

[0361] Embodiment 8. The method of any one of Embodiments 1-7. w herein the method treats, ameliorates, and / or prevents axon degeneration-associated disease or condition, and wherein the axon degeneration-associated disease or condition comprises Acute injury, Alzheimer's disease (including senile dementia of the Alzheimer type), amyloid related imaging abnormalities (ARIA), amyotrophic lateral sclerosis (ALS), cerebellar abiotrophy, cerebellar cortical degeneration, cerebral amyloid angiopathy (CAA), Charcot-Marie-Tooth disease (including inherited sensorimotor neuropathies and peroneal muscular atrophy), chemotherapy-induced peripheral neuropathy (CIPN), chronic progressive neuropathy, chronic traumatic encephalopathy (CTE), Cognitive Dysfunction Syndrome, corticobasal degeneration (CBGD) (including corticodentatonigral degeneration), degenerative

[0362] 44

[0363] 578220772Atorney Docket No. 394948-0104W01(00013)

[0364] myelopathy, demyelinating optic neuropathy (including ON associated with MS, MOGAD, and NMOSD), diabetic peripheral neuropathy (DPN). Down syndrome, familial tremor, frontotemporal dementia (FTD) (including Pick’s disease), Gilles de la Tourette syndrome, Hallervorden-Spatz disease, hereditary optic atrophy (Leber’s disease), hereditary spastic paraplegia, Huntington’s disease (HD), hypertrophic interstitial polyneuropathy (Dejerine-Sottas), Lewy body dementia, mild cognitive impairment (MCI), multiple system atrophy (MSA) (including Shy-Drager, striatonigral degeneration, and OPCA), neuroaxonal dystrophy, Parkinson’s disease, pigmentary degeneration of the retina (retinitis pigmentosa), post-traumatic stress, primary lateral sclerosis, prion-caused diseases, progressive supranuclear palsy (PSP) (including Steel-Richardson-Olszewski), spastic torticollis and other dyskinesis. spinal muscular atrophy, spinocerebellar degeneration (including Friedreich’s ataxia), stroke, tauopathies, torsion dystonia (including torsion spasm and dystonia musculorum deformans), traumatic brain injury, traumatic glaucoma, vascular dementias, white dog shaker syndrome, and / or white matter disease.

[0365] Embodiment 9. The method of Embodiments 8. axon degeneration-associated disease or condition is chemotherapy -induced peripheral neuropathy (CIPN).

[0366] Embodiment 10. The method of Embodiment 9, wherein the modulator is administered before or at about the same time as the chemotherapeutic agent.

[0367] Embodiment 11. The method of any one of Embodiments 1-8, wherein the method treats, ameliorates, and / or prevents axon degeneration, and wherein the axon degeneration is an axon degeneration in the peripheral nerves system (PNS).

[0368] The foregoing outlines features of several embodiments so that those skilled in the art may better understand the aspects of the present disclosure. Those skilled in the art should appreciate that they may readily use the present disclosure as a basis for designing or modifying other processes and structures for earn ing out the same purposes and / or achieving the same advantages of the embodiments introduced herein. Those skilled in the art should also realize that such equivalent constructions do not depart from the spirit and scope of the present disclosure, and that they may make various changes, substitutions, and alterations herein without departing from the spirit and scope of the present disclosure.

[0369] 45

[0370] 578220772

Claims

1. Attorney Docket No. 394948-0104W01(00013)CLAIMSWhat is claimed is:

1. A method of treating, ameliorating, and / or preventing axon degeneration or an associated disease or condition in a subject in need thereof, the method comprising administering to the subject a modulator of one or more selected from the group consisting of acyl-protein thioesterase (APT)-l, APT2, a / hydrolase domain-containing (ABHD) enzyme 16A, ABHD17A, ABHD17B, and ABHD17C,2. The method of claim 1, wherein the modulator is a compound that downregulates APT1, APT2, ABHD16A, ABHD17A, ABHD17B, and / or ABHD17C.

3. The method of any one of claims 1-2, wherein the modulator is a compound that downregulates APT1, APT2, ABHD16A, ABHD17A, ABHD17B, and / or ABHD17C, and comprises at least one selected from the group consisting of:a small molecule inhibitor of APT 1, APT2, ABHD 16 A, ABHD 17 A, ABHD17B, and / or ABHD 17C.an antibody for APT1, APT2, ABHD16A, ABHD17A, ABHD17B, and / or ABHD17C,anucleic acid that downregulates APT1, APT2, ABHD16A, ABHD17A, ABHD17B, and / or ABHD17C by RNA interference, and / or an expression vector expressing the same, a ribozyme that downregulates APT1, APT2, ABHD16A, ABHD17A, ABHD17B, and / or ABHD17C, and / or an expression vector expressing the same,an expression vector comprising an expression cassette, wherein the expression cassette expresses CRISPR components that downregulate APT1, APT2, ABHD16A, ABHD 17 A, ABHD17B. and / or ABHD17C by CRISPR knockout or CRISPR knockdown, anda trans-dominant negative mutant protein of APT1, APT2, ABHD16A, ABHD17A, ABHD17B, and / or ABHD17C, and / or an expression vector that expresses the same.

4. The method of any one of claims 1-3, wherein at least one of the following applies:(a) the modulator is a compound that downregulates APT1, and the compound is HDFP, ML-211, ML348, Palmostatin B (PalmB), and / or Palmostatin M (PalmM);46578220772Attorney Docket No. 394948-0104W01(00013)(b) the modulator is a compound that downregulates APT2, and the compound is HDFP, ML-211, ML349, PalmB, and / or PalmM;(c) the modulator is a compound that downregulates ABHD16A, and the compound is DH376, KC01, KT195, and / or (Z)-KC02(d) the modulator is a compound that downregulates ABHD17A, ABHD17B, and / or ABHD17C, and the compound is ABD778 and / or ABD957.

5. The method of any one of claims 1-4, further comprising administering to the subject an effective amount of a compound that dow regulates sterile alpha and toll / interleukin-1 receptor motif-containing 1 (SARM1).

6. The method of claim 5, wherein the compound that downregulates SARM1 comprises at least one selected from the group consisting of:a small molecule inhibitor of SARM1,an antibody for SARM1,a nucleic acid that downregulates SARM1 by RNA interference, and / or an expression vector expressing the same,a ribozyme that downregulates SARM1, and / or an expression vector expressing the same,an expression vector comprising an expression cassette, wherein the expression cassette expresses CRISPR components that downregulate SARM1 by CRISPR knockout or CRISPR knockdown, anda trans-dominant negative mutant protein of SARM1, and / or an expression vector that expresses the same.

7. The method of any one of claims 5-6, wherein the compound that that downregulates SARM1 comprises 5-chloroisoquinoline, berberine chloride, CZ-48 (Sulfo-ara-F-NMN), dHNN, dehydronitrosonisoldipine, DSRM-3716 (5-iodoisoquinoline), GNE-5152, hematoxylin, isoquinoline, NaMN (nicotinic acid mononucleotide), NB-3, NB-7, nicotinamide, phenazopyridine, phenazopyridine hydrochloride, RO-7529, SA91-0178, SIR2501, zinc chloride, or a compound of formula (I):47578220772Atorney Docket No. 394948-0104W01(00013)oCN(I),wherein:R1is phenyl, naphthyl, quinolinyl, or isoquinolinyl, any of which is optionally substituted with one or more optionally selected from the group consisting of C1-C3 alkyl, F, Cl, Br, I, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, and -SO2(Ci-C3 alkyl);R2is H or C1-C3 alkyl;or a pharmaceutically acceptable salt thereof.

8. The method of any one of claims 1-7, wherein the method treats, ameliorates, and / or prevents axon degeneration-associated disease or condition, and wherein the axon degeneration-associated disease or condition comprises Acute injury, Alzheimer's disease (including senile dementia of the Alzheimer type), amyloid related imaging abnormalities (ARIA), amyotrophic lateral sclerosis (ALS), cerebellar abiotrophy, cerebellar cortical degeneration, cerebral amyloid angiopathy (CAA), Charcot-Marie-Tooth disease (including inherited sensorimotor neuropathies and peroneal muscular atrophy), chemotherapy -induced peripheral neuropathy (CIPN). chronic progressive neuropathy, chronic traumatic encephalopathy (CTE), Cognitive Dysfunction Syndrome, corticobasal degeneration (CBGD) (including corticodentatonigral degeneration), degenerative myelopathy, demyelinating optic neuropathy (including ON associated with MS, MOGAD, and NMOSD), diabetic peripheral neuropathy (DPN). Down syndrome, familial tremor, frontotemporal dementia (FTD) (including Pick’s disease). Gilles de la Tourette syndrome, Hallervorden-Spatz disease, hereditary optic atrophy (Leber’s disease), hereditary spastic paraplegia, Huntington’s disease (HD), hypertrophic interstitial polyneuropathy (Dejerine-Sottas), Lewy body dementia, mild cognitive impairment (MCI), multiple system atrophy (MSA) (including Shy-Drager, striatonigral degeneration, and OPCA), neuroaxonal dystrophy. Parkinson’s disease, pigmentary' degeneration of the retina (retinitis pigmentosa), post-traumatic stress, primary' lateral sclerosis, prion-caused diseases, progressive supranuclear palsy (PSP) (including Steel-Richardson-Olszewski), spastic torticollis and other dyskinesis, spinal muscular atrophy, spinocerebellar degeneration (including Friedreich’s ataxia), stroke, tauopathies, torsion dystonia (including torsron spasm and dystonia musculorum deformans), traumatic48578220772Atorney Docket No. 394948-0104W01(00013)brain injur ', traumatic glaucoma, vascular dementias, white dog shaker syndrome, and / or white matter disease.

9. The method of claims 8, axon degeneration-associated disease or condition is chemotherapy -induced peripheral neuropathy (CIPN).

10. The method of claim 9, wherein the modulator is administered before or at about the same time as the chemotherapeutic agent.

11. The method of any one of claims 1-8, wherein the method treats, ameliorates, and / or prevents axon degeneration, and wherein the axon degeneration is an axon degeneration in the peripheral nerves system (PNS).49578220772